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National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Division of Tuberculosis Elimination 
ADVISORY COUNCIL FOR THE ELIMINATION OF TUBERCULOSIS 
June 9-10, 2014 
 
DRAFT Minutes of the Meeting 
The U.S. Department of Health and Human Services (HHS) and the Centers for Disease 
Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD and TB 
Prevention (NCHHSTP), Division of Tuberculosis Elimination (DTBE) convened a meeting of the 
Advisory Council for the Elimination of Tuberculosis (ACET).  The proceedings were held on 
June 9-10, 2014 in Building 8 of CDC’s Corporate Square Campus, Conference Room A/B/C, in 
Atlanta, Georgia. 
 
ACET is chartered to provide advice to the Secretary of HHS and the Director of CDC regarding 
the elimination of tuberculosis (TB); make recommendations regarding policies, strategies, 
objectives and priorities; address the development and application of new technologies; provide 
guidance on CDC’s TB Prevention Research portfolio and program priorities; and review the 
extent to which progress has been made toward eliminating TB.  
Opening Session: June 9, 2014 
Hazel Dean, ScD, MPH 
Deputy Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
ACET Designated Federal Officer (DFO) 
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Dr. Dean conducted a roll call to determine the ACET voting members, ex-officio members and 
liaison representatives who were attending the meeting either in person or remotely.  She 
announced that ACET meetings are open to the public and all comments made during the 
proceedings are a matter of public record. 
Dr. Dean reminded the ACET voting members of their responsibility to disclose any potential 
individual and/or institutional conflicts of interest for the public record and recuse themselves 
from voting or participating in these matters. 
CONFLICT OF INTEREST DISCLOSURES 
ACET Voting Member 
(Institution/Organization) 
Potential Conflict of Interest 
Ana Alvarez, MD, FAAP 
(University of Florida College of Medicine) 
No conflicts disclosed 
Eric Brenner, MD 
(Arnold School of Public Health 
University of South Carolina) 
No conflicts disclosed 
Marcos Burgos, MD 
(New Mexico Department of Health & 
University of New Mexico School of Medicine) 
No conflicts disclosed 
Jane Carter, MD 
(Alpert School of Medicine at Brown 
University & The Miriam Hospital) 
President of the International Union Against TB and 
Lung Disease (IUATLD) 
Gail Cassell, PhD 
(Harvard University 
Department of Global and Social Medicine) 
Participant in the Eli Lilly MDR-TB Partnership that 
established the Lilly TB Drug Discovery Initiative; 
Chair of the American Society for Microbiology 
Biomedical Research Committee of the Public and 
Scientific Affairs Board 
Jennifer Cochran, MPH 
(Massachusetts Department of Public Health) 
Grantee of the CDC TB Cooperative Agreement 
(CoAg) 
Barbara Cole, RN, MSN, PHN 
(Riverside County Department of Public 
Health) 
No conflicts disclosed 
Susan Dorman, MD 
(Johns Hopkinds University School of 
Medicine) 
No conflicts disclosed 
Robert Horsburgh, Jr., MD, MUS 
(Boston University School of Public Health) 
No conflicts disclosed 
Dr. Dean announced that the voting members and ex-officio members in attendance constituted 
a quorum for ACET to conduct its business on June 9, 2014.  She called the proceedings to 
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order at 8:32 a.m. and welcomed the participants to day 1 of the ACET meeting.  Dr. Dean 
noted the temporary and permanent changes to ACET’s membership. 
• Dr. Randall Reves has replaced Dr. Edward Nardell as the liaison representative for 
IUATLD.  Dr. Reves is the IUATLD President-elect. 
• Dr. Christopher Archibald would serve as the alternate liaison representative for the 
Public Health Agency of Canada in the absence of Dr. Howard Njoo. 
• Dr. Michael Bartholomew would serve as the alternate ex-officio member for the Indian 
Health Service in the absence of Dr. Susan Karol. 
• Dr. Susan Robilotto would serve as the alternate ex-officio member for the Health 
Resources and Services Administration (HRSA) HIV/AIDS Bureau in the absence of Dr. 
Rupali Doshi. 
• Ms. Sue Etkind would serve as the alternate liaison representative for Stop TB USA in 
the absence of Ms. Eileen Napolitano. 
• The U.S. Marshals Service is still in the process of identifying an ex-officio member to 
replace Ms. Tiffany Moore. 
• The terms of four ACET members would expire at the end of June 2014:  Drs. Eric 
Brenner, Marcos Burgos, Jane Carter and Gail Cassell.  However, the outgoing ACET 
members will serve for an additional 180 days until their replacements are formally 
approved.  The final nomination packages for the new members were submitted to the 
CDC Committee Management Office on May 28, 2014. 
Barbara Cole, RN, MSN, PHN, ACET Chair 
TB Controller 
Riverside County (California) Department of Public Health 
Ms. Cole joined Dr. Dean in welcoming the participants to day 1 of the ACET meeting.  She 
explained that a significant portion of the meeting would be devoted to a status report on the 
resolutions and recommendations ACET formally approved in 2011, 2012 and 2013.  During 
this discussion, the ACET members would be asked to provide concrete input on strategically 
advancing these items to assist CDC in achieving the national goal of TB elimination. 
Jonathan Mermin, MD, MPH 
Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
NCHHSTP Director’s Report 
Dr. Mermin covered the following topics in his Director’s report to ACET.  At the agency level, 
sequester reductions led to the restoration of $569 million in the FY2014 CDC budget.  CDC 
allocated $30 million of these funds to the National Center for Emerging and Zoonotic Infectious 
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Diseases to establish a new Advanced Molecular Detection (AMD) Program.  The AMD 
Program will target funding and efforts to five major activities. 
• Improved pathogen identification and detection 
• New diagnostics 
• Technical assistance (TA) to states to meet their bioinformatics and genomics needs 
• Enhanced laboratory information systems 
• Prediction, modeling and early recognition of infections 
CDC partnered with U.S. government (USG) agencies, other nations, international groups, and 
public/private stakeholders to launch a “Global Health Security Agenda.”  The purpose of this 
initiative is to accelerate progress toward achieving worldwide safety and security related to 
infectious disease threats and also to promote global health security in three major areas. 
First, the likelihood of natural, accidental or intentional outbreaks will be prevented and reduced.  
Second, threats will be detected early to save lives.  Third, multi-sectorial coordination and 
communication will be deployed internationally to ensure a rapid and effective response.  Due to 
increased concerns regarding antimicrobial resistance, CDC hopes to use the Global Health 
Security Agenda to allocate resources to TB. 
At the National Center level, NCHHSTP received ~$25.2 million from the sequester reductions 
that were restored to CDC’s FY2014 budget.  For TB initiatives, NCHHSTP allocated ~$2.1 
million primarily to restore cuts to the TB Prevention, Control and Laboratory CoAgs, 
Tuberculosis Epidemiologic Studies Consortium (TBESC), and Tuberculosis Trials Consortium 
(TBTC). 
CDC’s new AMD Program awarded $917,240 to NCHHSTP to conduct five new AMD projects. 
1. Characterization of microbial transmission networks by combining epidemiologic and 
genetic data 
2. Advanced molecular detection of hepatitis C virus outbreaks 
3. Genomic surveillance of Mycobacterium tuberculosis (M.tb) in New York City over the 
2011-2014 time period 
4. Whole-genome sequencing (WGS) for national TB outbreak detection and investigations 
5. Genomic sequencing of Neisseria gonorrhoeae to more effectively respond to the urgent 
threat of antimicrobial-resistant gonorrhea 
NCHHSTP implemented a new strategic planning process to identify the best approaches to 
achieve maximum impact on reducing health disparities, disease incidence, morbidity and 
mortality for HIV, viral hepatitis, STDs and TB.  NCHHSTP held meetings and retreats with staff 
at the Office of Director, division and branch levels to obtain internal input on the strategic 
planning process.  Key informant interviews also were conducted with partners to obtain 
external guidance on opportunities and challenges related to HIV, viral hepatitis, STD and TB 
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prevention.  After NCHHSTP develops the draft Strategic Plan, the document will be shared and 
vetted with a broader group of partners and stakeholders. 
NCHHSTP launched a new “Prevention Through Health Care” website as an online resource to 
help leverage changes in the healthcare system at multiple levels:  state, local and tribal public 
health agencies, community-based organizations and other partners.  NCHHSTP published 
success stories and outcomes of demonstration projects related to its Program Collaboration 
and Service (PCSI) initiative.  A supplement on PCSI also was published in the January/ 
February 2014 edition of Public Health Reports.  NCHHSTP published the 2013 Annual Report 
to highlight its center-wide activities and accomplishments.  NCHHSTP updated its “Atlas” with 
2012 surveillance data for STDs and TB.  All of these resources and publications are available 
on the CDC.gov/nchhstp website. 
NCHHSTP conducted a number of workforce development and capacity building activities.  A 
new seminar series on laboratory science was offered to epidemiologists.  A new scientific 
writing course was held for NCHHSTP scientists.  The Coaching and Leadership Initiative was 
piloted in 2013 with 60 team leaders.  NCHHSTP continued to conduct its Ambassador Program 
to assist new employees during their transition to the workforce. 
NCHHSTP recently announced the appointment of Dr. Stephanie Zaza as the new Director of 
the Division of Adolescent and School Health.  NCHHSTP expects to appoint permanent 
Directors for DTBE and the Division of HIV/AIDS Prevention over the next month. 
At the division level, DTBE released several publications in observance of World TB Day.  
DTBE published a Morbidity and Mortality Weekly Report (MMWR) article on March 21, 2014 to 
report TB trends in the United States in 2013.  TB cases are continuing to decline with 9,588 
cases reported in 2013.  Estimates indicate that U.S. TB prevention and control efforts have 
helped to prevent >200,000 cases since 1993.  However, dramatic disparities still exist with 
persistently higher TB rates among racial/ethnic minority groups than whites. 
DTBE published “Treatment Practices: Outcomes and Costs of Multidrug-Resistant and 
Extensively Drug-Resistant Tuberculosis in the United States, 2005-2007,” in Emerging 
Infectious Diseases in May 2014.  DTBE hosted a Public Health Grand Rounds in March 2014, 
“Multidrug-Resistant Tuberculosis, Tools for Tackling a New Face of an Old Foe.”  DTBE 
participated in a briefing with Congressional staffers in its ongoing efforts to increase the interest 
in and visibility of TB.  DTBE emphasized that CDC makes a sound return on TB investments 
Congress allocates to CDC. 
Acting DTBE Director’s Report 
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Philip LoBue, MD 
Acting Director, Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
Dr. LoBue covered the following topics in his Acting Director’s report to ACET.  Of DTBE’s 
FY2014 budget of ~$143 million, the actual spending amount is ~$138.7 million because a 
portion of the funds are set aside to support general activities at both the agency and center 
levels.  The FY2014 budget increase restored ~$2.1 million of the $7 million reduction in the 
FY2013 budget.  The line-items in the FY2014 budget increase included restoration of ~$1.4 
million to the TB Prevention, Control and Laboratory CoAgs; restoration of ~$440,000 to the TB 
research budget (~$250,000 to TBTC and ~$190,000 to TBESC); and a 1% cost-of-living 
adjustment based on a full-time equivalent (FTE) budget of $27 million (excluding contractors). 
DTBE had several changes in its leadership over the past few months.  Dr. Angela Starks 
replaced Dr. Michael Iademarco as Chief of the Laboratory Branch.  Dr. Bonnie Plikaytis will be 
retiring from her position as Deputy Chief of the Laboratory Branch.  Dr. Jose Becerra will be 
retiring from his position as Chief of the Data Management and Statistics Branch.  Searches will 
be initiated in the near future to permanently fill the two leadership positions. 
DTBE expects to publish the new 2015-2019 TB Prevention, Control and Laboratory Funding 
Opportunity Announcement (FOA) on July 1, 2014, announce the awards on December 1, 2014, 
and allocate funds to grantees on January 1, 2015.  After the FOA is published, applicants will 
be given 45 days to submit their applications through the Grants.gov website.  Eligibility for 
funding will be limited to state/local health departments that previously were TB CoAg grantees.  
The TB funding formula will be 100% implemented in 2015. 
DTBE will not revise the Report of Verified Case of Tuberculosis (RVCT) to capture molecular 
drug susceptibility testing data until input is obtained from a wide range of state partners.  To 
support the RVCT revisions, multiple systems would need to be updated because various 
programs utilize their individual systems to submit data to CDC’s central repository.  As a result, 
both CDC and individual TB programs would incur high costs and increased complexity.  In the 
interim, however, DTBE is coordinating efforts with partners to improve the RVCT instructions. 
DTBE received its second year of funding from the CDC Office of Antimicrobial Resistance to 
improve the accuracy of laboratory data reported through the RVCT.  DTBE established a new 
“Data Re-Release Agreement” that now allows CDC to report county-level data and conduct 
more granular analyses.  However, the rules regarding data suppression will be maintained to 
assure the protection and confidentiality of TB patients. 
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DTBE provided technical input and expertise to inform the U.S. Food and Drug Administration’s 
(FDA) decision-making process on the reclassification of molecular TB assays.  DTBE 
emphasized that reclassification of and special controls for molecular TB assays would lessen 
the burden on industry for commercialization of these devices, while mitigating their associated 
risks.  DTBE’s description of the public health benefits of these devices in diagnosing TB played 
a significant role in an FDA Advisory Panel unanimously voting in favor of reclassification.  In 
May 2014, FDA downgraded nucleic acid-based in vitro diagnostics to detect M.tb from 
respiratory specimens from the Class III, pre-market approval category to Class II with special 
controls. 
DTBE is extremely proud of the national leadership, accomplishments and future directions of 
its research consortia.  For TB epidemiologic research, TBESC initially conducted studies to 
compare the predictive value of three latent TB infection (LTBI) tests.  However, TBESC was 
unable to reach its sample size targets and gather statistically meaningful results due to the low 
rate of progression to TB disease and the minimal number of endpoints.  TBESC is now shifting 
the focus of its epidemiologic research for TB programs and community partners to track LTBI in 
populations at highest risk and maximize efforts to expand LTBI testing and treatment. 
For TB treatment research, TBTC has made significant contributions to the published literature.  
Study 26 is completed and compared a three-month, once-weekly isoniazid/rifapentine (3HP) 
regimen to a nine-month isoniazid (INH) regimen.  Study 26 led to the development of three new 
papers that are in various stages of publication:  submission of a pediatric sub-study 
manuscript, ongoing clearance of a hypersensitivity manuscript, and preparation of a draft HIV 
sub-study.  Study 29X is completed and examined a high-dose rifapentine (RPT) regimen for 
treatment of TB disease in a Phase II trial.  The manuscript for Study 29X is ready for 
publication at this time. 
Study 31 is pending and will be initiated in early 2015 to examine a four-month RPT-based 
regimen for treatment of TB disease in a Phase III trial.  DTBE and FDA will meet later in June 
2014 to discuss the study protocol.  Study 33 is underway and is examining self-administration 
of the 3HP regimen to gather more data on adherence and tolerability.  The major goal of the 
study will be to overcome major obstacles in directly-observed therapy that hinder broad 
implementation of an LTBI regimen.  Because the entire cohort has been fully enrolled at this 
time, Study 33 is expected to be concluded in August 2014. 
DTBE recently released four TB Self-Study Modules on the CDC.gov/tb website in addition to 
the “Introduction” and “Glossary.” 
• Module 6: “Managing Tuberculosis Patients and Improving Adherence” 
• Module 7: “Patient Rights and Confidentiality in Tuberculosis Control” 
• Module 8: “Contact Investigations for Tuberculosis” 
• Module 9: “Tuberculosis Outbreak Detection and Response” 
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DTBE initiated a strategic alignment process of its TB priorities, activities, staffing and budget 
after the 2013 budget sequestration.  DTBE realized that reactive across-the-board funding cuts 
would be unsustainable and eventually would lead to all major TB activities and programs (e.g., 
Regional Training and Medical Consultation Centers (RTMCCs), TBTC and TBESC) being 
under-funded and unable to meet goals.  DTBE agreed that the preferred approach would be to 
make strategic rather than across-the-board cuts to preserve higher priority activities and 
eliminate lower priority activities if the budget sequestration continued in the future.  DTBE also 
recognized that staff costs were growing at an unsustainable rate. 
Several events have impacted the timing and direction of DTBE’s strategic alignment process:  
the 2014 Omnibus budget that deferred the 2013 budget sequestration; restoration of a portion 
of funding to DTBE’s FY2014 budget; and the impact on current planning efforts due to 
upcoming changes in DTBE’s permanent leadership.  The stable FY2014 budget will ease the 
pressure of time constraints, but DTBE will maintain momentum of its current strategic planning 
efforts.  This process is valuable for advance planning and also will allow DTBE to consider 
level funding scenarios.   
DTBE formed three workgroups to propose agendas, priorities and contingency budget plans in 
the areas of staffing, research and program.  The Staffing and Research Workgroups completed 
and distributed their interim reports to ACET for review and comment, but the Program 
Workgroup currently is revising its interim report to address additional funding scenarios.  Key 
recommendations proposed by the Staffing and Research Workgroups and DTBE’s preliminary 







Establish a three-year target for DTBE 
personnel spending to achieve a reduction 
from $27 million to $24 million. 
DTBE will maintain personnel spending at $27 
million at this time.  Economizing measures 
proposed by the workgroup will be implemented 
when possible. 
Develop a strategy and a defined process to 
assess new hires from a division perspective.   
DTBE has implemented this process. 
Consider reorganizing DTBE by regrouping 
division functions to increase efficiency and 
flexibility. 
DTBE will defer its response in order for the 
permanent DTBE Director to weigh in and consider 
this suggestion. 
Encourage a robust culture of mentoring and 
opportunities for professional development of 
staff. 
DTBE strongly supports this suggestion, but 
specific and concrete input is needed from staff to 
make improvements in this area. 
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Strengthen oversight of the DTBE research 
portfolio with an internal oversight board and 
external peer review process. 
DTBE strongly supports this suggestion, but the 
final decision will be at the discretion of the 
permanent DTBE Director. 
Develop a method and criteria to establish and 
evaluate DTBE’s research priorities. 
Response pending. 
Emphasize the importance of supporting time-
limited innovative research projects because 
all of DTBE’s research funding and efforts are 
targeted to TBTC and TBESC at this time. 
Response pending. 
Advance to next steps: 
• Create an internal oversight board 
• Plan for an external peer review process 
• Develop and prioritize a list of current and 
potential research projects 
• Develop contingency planning to conduct TB 
research under various budget scenarios 
Response pending. 
 
ACET discussed the following topics with Dr. LoBue on DTBE’s recent activities. 
• Reasons for the delay in selecting a permanent DTBE Director. 
• The potential for the FY2015 budget to restore even more funding to the $7 million 
reduction in the FY2013 budget. 
• The anticipated timeline for DTBE to provide ACET with a list of its research priorities 
and division functions that will be reorganized and regrouped. 
• The anticipated timeline for DTBE to begin revising the RVCT. 
• The possibility of DTBE analyzing and demonstrating the increased cost per TB case 
due to the shift to TB elimination and the continued decline in the reported number of 
cases. 
• Expected changes in funding levels to states due to 100% implementation of the TB 
funding formula in 2015. 
• CDC’s programs and incentives to address attrition in the aging TB workforce due to 
retirements in DTBE and its funded state/local health department staff. 
• ACET’s future role, strategies and priorities to provide DTBE with the best advice during 
its reorganization and transition to new leadership. 
Dr. LoBue explained that most of ACET’s comments could not be addressed until after the 
permanent DTBE Director has been appointed, the FY2015 budget has been allocated by 
Congress, and the 2015-2019 TB CoAg has been awarded.  However, he responded to three of 
ACET’s questions.  In terms of DTBE’s research priorities, the Research Workgroup currently is 
developing an inventory of ongoing and emerging research projects.  After the list is prioritized 
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based on a specific set of criteria and budget scenarios, DTBE expects to convene an external 
peer review panel in 2015 to obtain broader input. 
In terms of the reorganization of division functions, DTBE needs to further analyze workforce 
statistics, field staff and other data to inform its decision-making.  In terms of ACET’s future 
advisory role, DTBE would benefit from guidance and input on broader issues.  For example, 
updates should continue to be placed on agendas, but future meetings should be structured for 
ACET to provide advice on a major theme or topic. 
The discussion resulted in ACET advising DTBE to engage an external group of industry 
experts to share their experiences and lessons learned in enrolling participants in domestic and 
international clinical trials.  ACET noted that this input would be valuable in helping the TBTC 
grantees to more rapidly identify and enroll the cohort for Study 31. 
CDC’s Strategic Approach to Reduce TB Among 
Foreign-Born Persons in the United States Through Global TB Activities 
Eugene McCray, MD 
Chief, International Research and Program Branch, DTBE 
Centers for Disease Control and Prevention 
Dr. McCray described CDC’s strategic approach to reduce TB among foreign-born persons 
(FBPs) in the United States through global TB activities.  CDC’s investment in global TB control 
is needed because TB elimination in the United States cannot be achieved if the global TB 
burden remains high and cross-border travel continues.  The percentage of TB cases among 
U.S.-born persons has dramatically decreased by ~63% since 2000, but has only declined by 
~18% among FBPs. 
The TB epidemic in the United States is highly concentrated to specific populations and 
geographic areas:  FBPs account for 64% of all cases; four high-burden states account for 50% 
of all cases; six countries account for 63% of all cases among FBPs (China, India, Kenya, 
Mexico, Philippines and Vietnam); and FBPs account for 91% of all multidrug-resistant TB 
(MDR-TB) cases. 
CDC’s global TB control activities are based on two global initiatives.  Strategy 1 is to achieve 
the global goals of the 2011-2015 Global Plan to Stop TB:  achieve the “1990” TB prevalence 
and mortality by 2015, reduce TB mortality by 75% by 2015, and reduce TB incidence by 50% 
by 2015.  The goal of TB elimination can be achieved by 2050 if the target of a 20% reduction in 
cases per year is met.  However, the current rate of decline is 2% of cases per year in the 
United States, 3%-4% of cases per year in China and Cambodia, and 10% of cases per year in 
Western Europe post-World War II. 
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Strategy 2 is to achieve the global goals of the 2010-2014 Lantos-Hyde USG Tuberculosis 
Strategy:  accelerate TB detection and treatment in 25 countries, scale-up prevention and 
treatment of MDR-TB, expand coverage and interventions for TB/HIV co-infection, and 
strengthen health systems.  CDC is extensively engaged with its global partners in revising the 
Lantos-Hyde USG TB Strategy for 2015.  
The DTBE International Research and Program Branch (IRPB) serves as the leader of CDC’s 
global TB control efforts, but other entities also play a major role in these activities.  The Division 
of Global Migration and Quarantine (DGMQ) is responsible for overseas screening and follow-
up of immigrants and refugees prior to U.S. entry.  The Global Disease Detection Branch is 
responsible for active case finding in hospital-based and outpatient-based settings in developing 
countries.  The Division of Global HIV/AIDS is responsible for delivering TB/HIV and other 
interventions in HIV settings. 
IRPB used the DTBE strategic planning process as an opportunity to identify major challenges 
in its leadership role for CDC’s global TB control efforts.  IRPB identified the first challenge as 
resources.  IRPB operates with an overall program budget of $7 million; 24 U.S.-based staff to 
support 31 countries; and 5.5 staff as in-country deployments in Botswana, China, India, Kenya 
and Thailand. 
IRPB identified the second challenge as the funding shortfall.  IRPB reviewed 2012 global 
mortality data that showed HIV accounted for 1.6 million deaths, TB accounted for 1.3 million 
deaths, and malaria accounted for 660,000 deaths.  However, USG and CDC resources for 
global TB control are not aligned with the epidemic because the least amount of funding for the 
three infectious diseases is allocated to TB. 
IRPB identified the third challenge as its future direction.  IRPB has been extremely successful 
in leveraging funds outside of CDC.  The President’s Emergency Plan for AIDS Relief, U.S. 
Agency for International Development (USAID) and other external sources account for ~75% of 
IRPB’s budget, while CDC contributes ~25% of funding.  Because IRPB’s projects and priorities 
are narrowly defined with scopes of work that are specific to these external funding streams, its 
activities have been viewed as being disconnected from and not significantly contributing to 
DTBE’s mission and mandate.  IRPB’s external funding sources also have limited its ability to 
coordinate and sustain efforts with internal CDC partners. 
IRPB shifted its traditional approach from ad hoc funding opportunities to a more strategic 
approach to address these challenges.  This effort includes the development of an evidence-
based, comprehensive, focused and coherent plan for global TB control to improve alignment 
between DTBE and IRPB priorities and achieve greater and more sustainable impact over time.  
IRBP branded its new effort with a vision of “A World Free of TB” and a mission of collaborating 
with partners to prevent TB transmission and reduce TB morbidity and mortality in target 
countries. 
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IRPB will conduct a number of activities to achieve the goals of its new strategic approach.  An 
evidence base will be built for effective TB control through basic epidemiology, clinical research 
and evaluation of new tools.  TB prevention and control will be improved through research and 
evaluation that are relevant to programs.  Technical support will be provided to build in-country 
capacity.  Public health systems will be strengthened by assessing weaknesses and guiding 
corrective actions.  Research will be translated into practice by informing and developing global 
TB control guidelines and policies.  Internal and external partnerships will be leveraged to 
access expertise and support that are necessary to achieve IRPB’s mission. 
IRPB reviewed recent data to identify countries for implementation of its strategic approach:  22 
high-burden countries that represent ~80% of global TB morbidity, 27 countries with the highest 
MDR-TB burden, and countries with the highest HIV burden.  IRPB then ranked the countries 
based on their disease burdens, contributions to TB among FBPs, and overall composite scores 
over the past five years. 
IRPB prioritized six countries for implementation of its new strategic approach after applying 
objective and subjective data and feasibility criteria:  Haiti, India, Kenya, Philippines, South 
Africa and Vietnam.  The six priority countries already have a USG presence and partnerships, 
strong political will, and significant resources from the Global Fund to Fight AIDS, Tuberculosis 
and Malaria.  TA and support will continue to be provided in other countries with a high TB 
burden on a case-by-case basis, but IRPB will dedicate 80% of its funding, staff and other 
resources to improve global TB control efforts in the six priority countries.  IRPB identified four 
focus areas that will be targeted to the six priority countries. 
Priority Area 1 
• Goal: Reduce TB among FBPs in the United States through research and program 
support in the priority countries 
• Approach: Decrease the overall TB burden in select countries where this strategy is 
most appropriate (e.g., countries with many U.S.-bound immigrants who do not undergo 
screening and/or countries with a large number of entrants to the United States) 
• Target Countries: Haiti, India, Philippines, Vietnam (Mexico to be added if political will 
and interest, a USG presence, and resources are obtained) 
Priority Area 2 
• Goal: Conduct research to decrease TB among U.S.-bound immigrants  
• Approach: Closely collaborate with DGMQ to conduct research and modeling to achieve 
the following outcomes:  (1) determine the best strategies to decrease TB among U.S.-
bound immigrants prior to U.S. entry; (2) identify FBPs at highest risk of progressing 
from LTBI to TB disease based on country of origin and other factors; and (3) expand 
screening of active TB to long-term visitors and students from high-risk countries 
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Priority Area 3 
• Goal: Guide global TB policies by providing innovative and impactful research and 
programmatic support 
• Approach: Conduct research and provide support to programs to determine the best 
strategies to accelerate the decline of TB in the priority countries 
• Target Countries: Haiti, India, Kenya, Philippines, South Africa, Vietnam 
Priority Area 4 
• Goal: Inform global TB control efforts by translating research into policy and practice 
• Approach: Apply evidence-based knowledge and research to inform policy and practice 
in the priority countries through collaboration with the World Health Organization (WHO), 
IUATLD and other international partners 
In addition to focusing on the four priority areas, IRPB also intends to increase its field presence 
in the six priority countries based on experiences and lessons learned.  In 1993-2011, for 
example, CDC had a consistent field presence in India that included direct TA, strong guidance 
and comprehensive support.  Data from IRPB’s ecological analysis showed that compared to 
China and other countries without CDC’s ongoing field presence, India had much more success 
in reducing TB incidence, influencing TB policy and directly impacting TB program activities. 
Overall, IRPB’s shift from an approach of missed opportunities to a comprehensive and 
synergistic strategy will more closely focus on global TB/HIV co-infection, MDR-TB and infection 
control in the six priority countries.  IRPB’s new strategic approach to reduce TB among FBPs in 
the United States also will enhance collaboration with DTBE’s surveillance, laboratory and 
training programs to increase overall impact. 
IRPB acknowledges that additional resources will be needed to successfully implement its new 
strategic approach:  more FTEs in the six target countries; dedicated CDC funding to conduct 
the priority activities; stronger internal and external coordination, particularly with the CDC 
Global Health Security Branch to leverage resources for antimicrobial resistance and MDR-TB; 
and advocacy and support from external partners and stakeholders.  IRPB hopes to make more 
rapid progress with its new strategic approach after the permanent DTBE Director is appointed. 
ACET discussed the following topics with Dr. McCray on CDC’s new strategic approach to 
reduce foreign-born TB cases in the United States. 
• The rationale for excluding China from the six priority countries:  (1) China is one of the 
major contributors to foreign-born TB cases in the United States.  (2) China is a global 
leader in MDR-TB research, surveillance, WGS, and provision of second-line drugs 
(SLDs) for TB. 
• Potential opportunities for CDC to take advantage of new requests for TA, programmatic 
research, evaluation or other aspects of the redesigned Global Fund to increase its field 
presence in the six priority countries. 
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• The possibility of CDC and WHO engaging the International Labour Organization as a 
new global partner due to the increased interest of this group in HIV/AIDS and other 
health aspects of the global workforce. 
• The need to increase TB screening of foreign-born minor children prior to U.S. entry. 
• CDC’s use of vitamin D therapy as an intervention for TB in overseas populations. 
• Barriers to USG implementation of global TB control activities in Russia. 
The discussion resulted in ACET making two key suggestions for CDC to consider in refining its 
new strategic approach to reduce foreign-born TB cases in the United States. 
• CDC is continuing to engage Ministries of Health (MOHs) in its global TB control efforts, 
but more emphasis should be placed on involving, educating and obtaining endorsement 
from Ministries of Finance that control in-country funding, program implementation and 
staffing. 
• CDC intends to add Mexico as a priority country if political will and interest, a USG 
presence and resources are obtained.  However, a more proactive approach should be 
taken because Mexico accounts for ~30% of foreign-born TB cases in the United States.  
ACET should devote time during a future meeting to propose effective strategies for 
CDC to leverage support, resources and endorsement for TB from the Mexico MOH.  
For example, CDC and its global partners currently are revising the Lantos-Hyde USG 
TB Strategy for 2015.  ACET should draft language for the updated strategy to 
emphasize the critical need to include Mexico as a priority country for TB among FBPs in 
the United States.  The focus on this issue should include Latin America as well. 
Overview of the U.S. Preventive Services Task Force (USPSTF) Draft Research Plan 
Christine Ho, MD, MPH 
Medical Officer, Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
Advice Requested from ACET by DTBE: 
• What is ACET’s input on the inclusion or exclusion of public health clinics in the USPSTF 
recommendations? 
• What is ACET’s input on specific patients who should be excluded from the USPSTF 
recommendations? 
 
Dr. Ho presented an overview of the USPSTF draft research plan that will serve as the basis to 
assess the evidence for LTBI treatment as prevention.  The Affordable Care Act (ACA) requires 
coverage of preventive services with a USPSTF Grade A or B recommendation without cost 
sharing for newly insured patients.  The CDC Advisory Committee on Immunization Practices 
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and HRSA recommendations call for TB testing of children at high risk for TB (e.g., children with 
foreign-born parents or recent exposure to TB). 
USPSTF gave LTBI screening of high-risk persons a Grade A recommendation in 1996, but did 
not renew the grade in its 2002 recommendations.  Instead, USPSTF’s guidance recognized the 
importance of targeted screening for TB and deferred to CDC’s guidelines for LTBI testing.  
CDC and the Agency for Health Research and Quality jointly funded a review in 2013 to inform 
USPSTF’s systematic review of the evidence for LTBI screening. 
USPSTF’s scope covers the provision and grading of recommendations on screening, but not 
treatment.  USPSTF’s recommendations typically are limited to asymptomatic patients in 
primary care settings and are based on its systematic reviews of the existing published literature 
rather than primary research.  USPSTF’s process for its systematic review of LTBI screening is 
outlined below. 
USPSTF drafted a research plan in collaboration with researchers from the Evidence-Based 
Practice Center (EPC) to guide the development of the LTBI screening recommendation.  The 
draft research plan has been posted on the USPSTF website for a 30-day public comment 
period and will be finalized after all of the comments have been reviewed and addressed.  The 
EPC researchers will use the final research plan to conduct a systematic review of the published 
evidence and draft an evidence report.  The systematic review will be based on studies 
published since 1996, but older data that are relevant to addressing the key questions will be 
considered as well. 
The draft evidence report will be posted on the USPSTF website for public comment and will be 
finalized after all of the comments have been reviewed and addressed.  USPSTF will use the 
final evidence report to draft the LTBI screening recommendation.  The draft recommendation 
will be posted on the USPSTF website for public comment.  All of the comments will be 
reviewed and addressed.  The final LTBI screening recommendation will be published based on 
USPSTF’s vote to ratify.  CDC expects the entire process to be completed by the end of 2015. 
USPSTF will use a series of structured key questions (KQs) to guide the systematic review of 
the evidence for the LTBI screening recommendation. 
Benefits of screening:  Does screening for the disease result in decreased incidence?  Does 
screening result in reduced morbidity or mortality?  Are screening tests accurate? 
• KQ 1:  What is the direct evidence that targeted screening for LTBI in asymptomatic 
adults at increased risk for developing active TB (such as persons in populations with a 
high prevalence of active TB or with documented increased risk for progression from 
LTBI to active TB) in primary care settings improves quality of life and reduces the 
incidence of active TB infection, transmission of TB and mortality? 
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Risks of screening:  What are the harms to screening or the diagnostic work-up? 
• KQ 2a:  What is the accuracy and reliability of using either tuberculin skin tests (TSTs) or 
interferon-gamma release assays (IGRAs) for screening asymptomatic adults who are at 
increased risk for developing active TB? 
• KQ 2b:  What is the accuracy and reliability of using sequential screening (e.g., TST 
followed by IGRA for persons with a particular TST result) in adults who are at increased 
risk for developing active TB? 
Benefits of treatment 
• KQ 3a:  For adults with LTBI, to what extent does treatment using recommended 
pharmacotherapy regimens improve quality of life and reduce progression to active TB, 
transmission of TB and mortality? 
Harms of screening 
• KQ 4:  What harms (including false-positive results, anxiety, labeling and stigma) are 
associated with screening for LTBI? 
• KQ 4a:  How do the harms differ by screening method or screening strategy? 
• KQ 4b:  How do the harms differ by populations screened? 
Harms of treatment 
• KQ 5:  What are the harms associated with treatment of LTBI using CDC-recommended 
pharmacotherapy regimens? 
The USPSTF draft research plan includes a proposed analytic framework that will be used to 
apply the KQs.  KQ 1 will be used to determine the impact of LTBI screening on active TB, 
reduction in transmission of TB, improved quality of life, and mortality among asymptomatic 
adults in higher risk populations.  KQ 2 will be used to determine the accuracy of screening tests 
in diagnosing LTBI.  KQ 3 will be used to determine whether treatment results in a reduction of 
active TB transmission, morbidity and mortality among persons with LTBI.    KQs 4 and 5 will be 
used to determine the harms of LTBI screening and treatment. 
In addition to the structured KQs, the USPSTF draft research plan also proposes five contextual 
questions that will be considered in the systematic review of the evidence for the LTBI screening 
recommendation. 
1. What are the estimated U.S. adult prevalence rates of LTBI and active TB in populations 
at increased risk for TB receiving care in primary care settings, including limitations or 
uncertainties regarding these prevalence rate estimates? 
2. What proportion of U.S. adults receiving care in primary care settings are members of 
these populations at increased risk? 
3. What populations of active TB cases in U.S. adults originate in these populations at 
increased risk? 
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4. What is the evidence on the incremental net benefit of more or less frequent screening 
for LTBI using different screening intervals in adults at increased risk in primary care 
settings? 
5. What is the reported frequency of LTBI screening in U.S. adults in primary care settings, 
both overall and for populations at increased risk? 
CDC identified topics for discussion in two key areas in its review of the USPSTF draft research 
plan.  Topic 1 is the role of public health clinics.  USPSTF recommendations traditionally have 
been targeted to primary care providers, but public health clinics historically have served as the 
setting for LTBI preventive care and treatment for underserved or marginalized patients with no 
other access to care. 
Topic 2 is a clear definition of patient populations.  Patients who are tested and treated for LTBI 
as part of a standard disease management protocol would not be included in the USPSTF 
recommendation for LTBI screening.  For example, HIV-infected patients or patients with 
rheumatoid arthritis on TNF blockers would be excluded from the systematic literature review 
and the USPSTF recommendations.  However, some patients who are proposed to be excluded 
(e.g., patients with head/neck cancer) do not have well-known disease management protocols 
that would guarantee automatic LTBI screening by their providers. 
Dr. Ho noted that the USPSTF draft research plan was distributed to ACET for review and 
comment.  As the external advisory body for CDC’s TB Prevention Research portfolio, she 
hoped ACET would set aside time during the meeting to draft a formal response to the plan.  
She pointed out that the public comment period would close on July 2, 2014. 
ACET discussed the following topics with Dr. Ho on the USPSTF draft research plan. 
• The inability of the systematic review to determine improved quality of life, a reduction in 
TB transmission, and decreased TB mortality because these endpoints are based on 
treatment outcomes rather than existing studies in the published literature. 
• The absence of public health representation and expertise on the USPSTF to address 
population-based issues. 
Ms. Cole confirmed that ACET would revisit the USPSTF draft research plan for LTBI screening 
during its upcoming discussion on DTBE’s proposed research agenda.  She also noted that 
ACET would have an opportunity during the Business Session on the following day to draft and 
vote on its formal response.  In the interim, several ACET members suggested issues that 
should be addressed in its formal response. 
• Clear prevention messages should be directed to both primary care and public health 
settings.  For example, all patients on TNF blockers are not routinely screened for LTBI 
as part of a standard disease management protocol. 
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• DTBE should gather and provide USPSTF with relevant TBESC data.  For example, 
data from Task Order 9 could be used to identify high-risk patients who were seen in 
primary care settings, but were not screened for LTBI.  TBESC genotyping data also 
could be used to determine the percentage of reactivation cases. 
• A distinction should not be made between primary care and public health settings due to 
the critical role and existing expertise of public health clinics.  For example, primary care 
providers can evaluate patients for LTBI screening, but public health clinics also need to 
be extensively involved with these cases due to the nature of TB transmission. 
• Data from TB contact investigations should be considered in the USPSTF systematic 
review. 
• USPSTF should be given solid definitions and examples that make a clear distinction 
between persons at “increased” and “high” risk for developing active TB. 
Overview of CDC’s New Advanced Molecular Detection Program 
 
Ed Ades, PhD 
Associate Director for Laboratory Science 
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
Dr. Ades presented an overview of CDC’s new AMD Program.  CDC initiated this effort based 
on the results of an internal review that showed outdated technology and insufficient capacity in 
its AMD approaches and bioinformatics methods.  CDC submitted a proposal to the President’s 
budget with a request of $40 million to make improvements in these areas, but the actual 
allocation was $30 million/ year for a five year period beginning in FY2014. 
CDC’s release of a call for research proposals in March 2014 to its three National Centers in the 
Office of Infectious Disease and the Center for Global Health resulted in the submission of 72 
AMD related proposals.  CDC funded 23 proposals based on the outcomes of the scientific 
review and evaluation process.  However, CDC will need to identify effective strategies to 
sustain the AMD Program over time, particularly since funding for years 3-5 is not guaranteed. 
CDC formed a Planning Team to clearly define the goals, metrics, focus areas and cross-cutting 
functional categories of the AMD Program that will be reported to Congress.  For example, 
years 1-2 funding will be used to build a strong infrastructure, enhance capacity and provide 
training for AMD, bioinformatics and information technology at CDC and in state public health 
laboratories. 
The Planning Team also will develop a communications plan and a dedicated website to ensure 
that partners, other stakeholders and the public are regularly informed and engaged in the AMD 
Program.  Most notably, CDC will collaborate with state partners in prioritizing state PHL 
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projects as part of the AMD projects.  CDC established a Steering Committee to provide 
oversight and input on efforts by the Planning Team. 
The key features of CDC’s new AMD Program are highlighted as follows.  CDC will use the 
AMD Program to link the five-year, high-level spending plan to individual goals and functional 
categories.  CDC will use the AMD Program to enhance its microbiology and bioinformatics 
capabilities to detect and prevent infectious disease outbreaks by conducting five major 
activities. 
• Improve pathogen identification and detection 
• Adapt new diagnostics to meet evolving public health needs 
• Assist states in meeting their future reference testing needs in a coordinated manner 
• Implement enhanced, sustainable and integrated laboratory data systems 
• Develop prediction, modeling and early recognition tools 
CDC will use the AMD Program to combine the cutting-edge approaches of bioinformatics, 
traditional epidemiology and genomic sequencing.  The foundation of genetic analyses, samples 
and sequenced generations, and epidemiology will allow CDC to more easily make an 
association to disease and prevalence.  CDC will use the AMD Program to improve public 
health through new technologies.  Genomic sequencing will be used to achieve earlier case 
recognition and reporting, more rapid and targeted outbreak responses, and the prevention of 
more potential cases. 
CDC will use the AMD Program to enhance its focus on transmission networks.  The inference 
of transmission networks will facilitate epidemiologic investigations to better understand the 
spread of infectious diseases and antimicrobial drug resistance.  Epidemiologic data (e.g., age, 
gender, causative agent, disease, partners, number of infections, location and environmental 
source) traditionally have been used to determine transmission networks and characterize 
persons in specific genetic networks. 
Sequencing technologies have replaced traditional methods by using microbial genetic data 
(e.g., single nucleotide polymorphism (SNP), sub-genome or WGS) to determine transmission 
networks.  Methods that combine sequence analyses and epidemiologic data are lacking, but 
are needed to characterize networks and target prevention efforts. 
CDC will use the AMD Program to align its existing prevention goals with new efforts to reduce 
transmission networks, particularly those with multiple links.  This strategy can be adapted for 
any pathogen or emerging infection to reduce the number of new infections, decrease 
transmitted drug resistance, and increase awareness of infection status.  The approach of 
targeting prevention efforts to reduce transmission networks has been applied to outbreak 
investigations and population-based prevention efforts. 
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CDC will use the AMD Program to focus on molecular epidemiology of microbes.  Microbial 
sequences can be unique to each infected individual.  Many microbes are measurably evolving 
pathogens that accumulate sequence diversity within hosts.  Microbial sequences can be 
examined to gather evidence on a recent association to infer potential transmission links.  
Microbial sequences have been successfully used to detect transmission clusters of several 
infectious diseases, including HIV, TB, hepatitis C, drug-resistant gonorrhea and bacterial 
infections. 
CDC will use the AMD Program to conduct two major bioinformatics activities:  (1) develop 
computational methods to study the structure, function and evolution of genes, proteins and 
whole genomes and (2) develop methods to manage and analyze biological data arising from 
genomics and high-throughput biological experiments. 
CDC has been challenged in leveraging bioinformatics expertise due to competition with 
industry and other entities.  Most notably, CDC has filled only 4 of its 25-30 new bioinformatics 
positions and fellowships to date.  CDC’s projections show that at least 33% of the public health 
laboratory workforce will need bioinformatics skills over the next five years to remain competitive 
with the private sector in the areas of point-of-care, diagnostics and genomic sequencing.  CDC 
is aware of the critical need to train current and new public health staff in bioinformatics to be 
competitive and maintain pace with the private sector. 
CDC will use the AMD Program to develop a bioinformatics pipeline that will improve its 
capacity to conduct epidemiologic and laboratory investigations, perform data searches, analyze 
and visualize data, and report results to state and local partners.  The bioinformatics pipeline will 
include the collection of patient data, generation of sequence data, merger of epidemiologic and 
laboratory data into a single database, automated searches and extractions of genotype drug-
resistant cases, and a standardized template for state/local partners to report results and 
identify targeted interventions. 
CDC will use the AMD Program to conduct molecular surveillance that will include sequences, 
computer modeling of bioinformatics and epidemiologic data to generate transmission links.  
These data can then be used for global molecular tracking. 
At the division level, CDC awarded funding to DTBE to conduct two projects under the AMD 
Program.  DTBE will weigh the advantages and disadvantages of conventional genotyping 
versus WGS.  In terms of conventional genotyping, the CDC National TB Genotyping Service 
genotypes one isolate from each culture-confirmed TB case in the United States.  A genotype 
cluster is formed when M.tb isolates are collected from at least two TB cases that share the 
same genotype. 
Conventional genotyping methods have been targeted toward regions of the genome that are 
known to vary among M.tb strains.  These targets are stable over long periods of time.  To date, 
>10,000 different genotypes have been identified.  However, conventional genotyping only 
 
DRAFT Minutes of the Meeting 
Advisory Council for the Elimination of Tuberculosis 
June 9-10, 2014  ♦  Page 21 
 
examines <1% of the genetic content of the complete M.tb genome.  Moreover, conventional 
genotyping data are difficult to interpret when highly related strains continue to circulate in 
communities for long periods of time. 
In terms of WGS, >90% of the genetic content of the complete M.tb genome can be examined.  
Mutations accumulate at a rate of 0.5 SNPs per year.  However, DTBE will be challenged by 
conducting WGS on TB clinical specimens rather than isolates.  Moreover, “unclean” samples in 
meta-genomics that will require TB and host DNA to be separated will impair DTBE’s ability to 
conduct WGS.  The goals, approaches and expected outcomes of DTBE’s two AMD projects 
are outlined below. 
DTBE AMD Project 1 
• Determine whether WGS can improve the accuracy of TB outbreak detection and the 
effectiveness of TB outbreak investigations. 
• Conduct WGS for all suspected large TB outbreaks identified through genotyping 
surveillance and compare these findings to epidemiologic data to determine the spread 
of infection and any potential linkages between cases. 
• Demonstrate whether public health resources could be more efficiently targeted if WGS 
has the ability to improve the accuracy of TB outbreak detection. 
• Demonstrate the greater impact of public health interventions if field investigations have 
stronger capacity to identify the spread of infection and pinpoint geographic locations 
that are most important to TB outbreaks. 
DTBE AMD Project 2 
• Review genomic M.tb surveillance data from the New York City 2011-2014 dataset that 
already has been used to discover previously undetected transmission of TB by locating 
cases caused by the same bacterial strain. 
• Use the New York City dataset to identify flaws in the traditional approximation-based 
approach for genotyping (e.g., false clustering of “different” isolates that actually are the 
same according to the remainder of the M.tb genome). 
• Demonstrate whether the use of WGS will result in different outcomes in the New York 
City dataset:  examination of >90% of the M.tb genome; provision of more precise data 
to public health officials to detect and more rapidly response to TB outbreaks; and 
enhanced ability to more strongly focus investigations on truly clustered cases. 
ACET discussed the following topics with Dr. Ades on CDC’s new AMD Program. 
• The ability of WGS/bioinformatics to make more rapid progress in TB control as opposed 
to proper and full implementation of existing tools for TB prevention and control. 
• The possibility of replicating the U.K. model in the United States in which WGS is used 
for management of difficult TB cases. 
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The discussion resulted in ACET making several recommendations for CDC to consider in 
implementing its new AMD Program. 
• CDC should consult with the Clinton Health Access Initiative because this organization 
plays a major role in TB bioinformatics.  Ms. Colleen Daniels, liaison representative for 
the Treatment Action Group, will provide CDC with point-of-contact information. 
• States have limited resources and capacity to analyze or take other actions with its TB 
molecular epidemiology, genotyping or WGS data.  A portion of AMD Program funding 
should be set aside and directly targeted to building an infrastructure in states at the 
outset to assure application of these data for case management in the field. 
• CDC should reconsider its focus on attempting to recruit persons with expertise in 
bioinformatics.  These personnel might not be needed due to new analytics, algorithms 
and other technologies that currently are being utilized for other bacterial infections and 
diagnostics. 
In response to one of ACET’s suggestions, Dr. Ades confirmed that CDC is exploring several 
options to address the lack of AMD resources and capacity in states.  Option 1 would be 
regionalization in which states would submit their samples to a centralized source in the region 
to conduct WGS.  Option 2 would be the deployment of CDC staff to states to build capacity in 
conducting WGS.  Option 3 would be CDC’s purchase of equipment for states to conduct 
genotyping and WGS and submit their data to CDC for analysis.  CDC would then provide each 
state with a report of its individual data analysis results. 
ACET Discussion: Resolution/Recommendation Process 
 
Barbara Cole, RN, MSN, PHN, ACET Chair 
TB Controller 
Riverside County (California) Department of Public Health 
Ms. Cole moderated the two parts of ACET’s discussion on its resolution/recommendation 
process.  For part 1 of the discussion, DTBE prepared and distributed three spreadsheets with 
all of the items that were placed for formal ACET votes in 2011, 2012 and 2013.  Ms. Cole 
asked DTBE to describe its plans to address the unresolved items.  She also encouraged ACET 
to provide DTBE with additional guidance on “partially implemented” items and propose next 








2011-1 DTBE to collect outcome data for all patients 
whose specimens are submitted to the 
Dr. LoBue will provide ACET with a 
response on whether the manuscript 
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Molecular Detection of Drug Resistance 
Service. 
that is being prepared for this project 
specifically addresses the resolution. 
2011-3 DTBE to update the guidelines on TB 
prevention and control among the homeless. 
Dr. LoBue will provide ACET with a 
timeline on when the Homeless 
Workgroup expects to complete the 




DTBE to conduct various activities to address 
racial/ethnic disparities in TB: 
• Commission or perform studies to enable an 
estimation of the attributable risks of 
established acquired and genetic risk factors 
within major racial/ethnic groups (2011-5b). 
• Commission or perform studies to enable an 
estimation of the attributable risks of vitamin 
D deficiency within major racial/ethnic 
groups (2011-5c). 
• Institute routine surveillance of presentation 
with cavitary disease with major racial/ethnic 
groups as an indicator of presumed 
treatment delay (2011-5d). 
ACET advised DTBE to fully 
implement these items by conducting 
rigorous epidemiologic analyses and 
presenting these data to ACET for 
review.  The analyses should identify 
disparities in TB by geographic 
location, racial/ethic group (particularly 
among African Americans), and drug 
use history. 
2011-6 DTBE to routinely report on the health equity 
implementation and evaluation plans as put 
forth by the NCHHSTP Office of Health Equity. 
Dr. Dean will schedule an update on 
NCHHSTP’s recent health equity 
activities for the next ACET meeting.  
The presenter will be Dr. Wayne 
Duffus, Associate Director for Health 
Equity in NCHHSTP.  
2011-15 ACET to establish a new “TB Elimination 
Workgroup.” 
ACET will discuss whether the 
workgroup fulfilled its charge or if 
current members should volunteer to 
reestablish the workgroup. 
2011-22 CDC to assess the public health benefits and 
cost effectiveness of NCHHSTP’s activities 
and demonstrate how these activities support 
TB elimination efforts and impact TB morbidity. 
ACET will discuss this item to provide 
DTBE with clearer guidance and 
propose next steps. 
2013-1 DTBE to extend the timeline of the ACET 
National TB Program Workgroup. 
ACET will discuss whether the 
workgroup fulfilled its charge during 
the six-month extension or if current 
members should volunteer to 
reestablish the workgroup. 
2013-4 ACET to conduct activities to “recast core TB 
program components in a period of 
ACET’s initial document on Bacille 
Calmette-Guerin vaccination for TB 
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epidemiologic, financial and healthcare system 
change.” 
was expanded to include additional 
infection control measures for U.S. 
healthcare providers and other citizens 
who would be working abroad.  The 
paper has been accepted by a journal 
for publication.  ACET will be provided 
with the link after the paper has been 
published. 
2013-6 The HHS Secretary to direct FDA to facilitate 
the importation of WHO-qualified SLDs. 
CDC initiated several activities to 
respond to this item.  FDA eventually 
informed CDC that non-approved 
drugs manufactured overseas cannot 
be imported into the United States.  
However, ACET will discuss next steps 
to determine whether the HHS 
Secretary reviewed and responded to 
its letter on this important issue. 
2013-7 CDC to make efforts on obtaining a USPSTF 
Grade A or B recommendation for LTBI 
treatment as prevention. 
The USPSTF draft research plan for 
LTBI screening was distributed to 
ACET for review.  ACET will draft and 
vote on its formal response to the 
research plan. 
2013-9 The ACET Chair to submit ACET’s 2011-2013 
report to the HHS Secretary. 
The HHS Secretary sent a letter to 
acknowledge that ACET’s 2011-2013 
report was received and reviewed.  
ACET will discuss next steps for the 
new HHS Secretary to take action on 
the issues outlined in the report. 
2013-10 CDC to make efforts on improving TB 
screening of H-1B work visa applicants. 
DGMQ will continue to provide regular 
updates to and obtain guidance from 
ACET on this issue.  ACET will discuss 
a process to provide input at a higher 
level to the G8 and G20. 
2013-16 ACET to draft a letter to the HHS Secretary 
and Dr. Thomas Frieden, Director of CDC, to 
emphasize the potential impact of funding cuts 
on TB programs. 
Because no action was taken in this 
regard, ACET will determine whether 
the letter is still needed. 
For part 2 of the discussion, Ms. Cole summarized the key components of ACET’s charter, 
including its authority, objective and scope of activities, description of duties, and reporting 
authorities.  She asked ACET to determine whether its current resolution/recommendation 
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process is the best approach to provide advice to the HHS Secretary and CDC Director on 
reaching the goal of TB elimination.  She also asked ACET to propose options to improve its 
advisory role. 
• DTBE was unable to implement some of ACET’s formally approved items in the past 
(e.g., new guidelines, studies or data collection efforts) due to competing priorities, lack 
of staff and/or limited funding.  As a result, ACET’s advisory role should be more aligned 
with, targeted to and focused on existing activities in DTBE’s portfolio for TB prevention, 
control and elimination.  A strategic approach with input on existing and planned 
initiatives rather than recommendations for new efforts will enhance DTBE’s ability to 
prioritize and conduct more of ACET’s formally approved items.  ACET’s strategic 
approach to providing guidance also will be important for DTBE’s transition to new 
leadership, shift to a healthcare reform environment, and efforts to address budget 
constraints. 
• ACET should formulate and direct its guidance to topics that are permitted by external 
advisory bodies, but are prohibited by federal agencies (e.g., funding or controversial 
issues). 
• ACET should continue to propose resolutions/recommendations for action, but with a 
significant reduction in the number of these items.  In the past, for example, ACET 
formally approved items that focused on the institutions or organizations of its ex-officio 
members and liaison representatives.  In the future, ACET should thoughtfully consider 
and limit its formally approved items to activities in DTBE’s long-term strategic plan for 
TB and also to broad, overarching and important public health issues that the HHS 
Secretary should address at a higher level outside of CDC.  Moreover, agendas should 
only include presentations that directly respond to ACET’s charge to address TB 
elimination. 
• ACET and DTBE should develop meeting agendas to resolve problems with timely and 
efficient follow-up and tracking of formally approved items.  For example, agendas 
should set aside time for ACET and DTBE to fully address old business items from the 
previous meeting before the members propose new business items during the current 
meeting.  ACET also should use regular status reports as an opportunity to evaluate the 
impact of its formally approved items on TB elimination efforts over time. 
• The ACET Chair and DFO should schedule a briefing with Dr. Frieden or his designee 
after each in-person meeting to summarize key outcomes and elevate the importance of 
TB at the level of the CDC Director. 
• The Research Workgroup for the DTBE strategic alignment process proposed the 
formation of a new external peer review panel to strengthen oversight of CDC’s TB 
research portfolio.  According to the description of duties in its charter, however, ACET is 
charged with providing guidance and reviewing CDC’s TB Prevention Research portfolio 
and program priorities.  A process should be established for DTBE to leverage expertise 
from ACET and other sources to provide a critical review and rigorous evaluation of its 
TB research portfolio. 
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• ACET’s resolution/recommendation process typically has focused on small, important 
issues for TB prevention and control, but its guidance should be at a much higher level 
to address the broader scope of TB elimination. 
o The 2000 Institute of Medicine (IOM) report included several recommendations to 
accelerate progress toward TB elimination.  The IOM report advised the HHS 
Secretary to routinely report on the status of implementing these recommendations, 
but no action has ever been taken in this regard.  ACET should provide the HHS 
Secretary with concrete action steps to make progress on implementing the IOM 
recommendations for TB elimination. 
o ACET’s guidance to the HHS Secretary has emphasized the importance of 
addressing the SLD shortage.  However, ACET should provide the HHS Secretary 
with concrete action steps to develop an entirely new TB regimen as recommended 
by the Federal TB Task Force in 1992 and 2009. 
• ACET should increase its prominence, visibility and recognition in the broader TB 
community to accelerate progress in TB elimination. 
o ACET should publish guidelines, position statements and other documents that 
would be independent of CDC and would not require CDC clearance and approval.  
ACET’s paper on infection control measures for U.S. citizens working abroad that 
has been accepted for journal publication should serve as a model in this effort. 
o ACET should be informed of activities in the broader TB community through regular 
updates from its liaison representatives and ex-officio members (e.g., Department of 
Defense, Department of Veteran Affairs and FDA). 
o ACET should galvanize partners across the country to develop, obtain approval and 
leverage funding for a President’s Strategic Plan for TB Elimination.  Dr. John Ward, 
Director of the NCHHSTP Division of Viral Hepatitis, should be invited to a future 
ACET meeting to describe experiences and lessons learned in the creation of the 
National Viral Hepatitis Action Plan that could be applied to TB. 
o ACET should replicate the HIV model for TB in which more emphasis is placed on 
providing broad guidance on the social determinants of health that drive an 
epidemic, such as poverty, no insurance coverage and homelessness. 
o ACET should direct more efforts to educating the broader TB community by 
compiling, disseminating and presenting key outcomes from its meetings to 
stakeholder organizations. 
Dr. Dean advised ACET to review experiences and lessons learned from the meeting structure 
and resolution process of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD 
Prevention and Treatment (CHAC).  For example, ACET takes an opportunistic approach in 
formulating guidance, while CHAC develops its agendas based on a few important themes and 
then proposes resolutions in response to these strategic issues.  Dr. Dean emphasized that a 
strategic rather than an opportunistic approach would improve ACET’s advice to the HHS 
Secretary and CDC Director. 
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Ms. Cole noted that based on the discussion, ACET would reorganize and restructure its current 
resolution/recommendation process to ensure its business is conducted with a more strategic, 
focused and global approach.  Due to the ability, expertise and passion of its membership, she 
was confident that ACET could advance beyond providing guidance on TB prevention and 
control to focus more on TB elimination. 
ACET Discussion: DTBE Research Agenda 
 
Barbara Cole, RN, MSN, PHN, ACET Chair 
TB Controller 
Riverside County (California) Department of Public Health 
Ms. Cole moderated ACET’s discussion on the TB research agenda that was proposed during 
the DTBE strategic planning process.  She noted that the interim report by the DTBE Research 
Workgroup was distributed to guide ACET’s discussion. 
• Synergy, research opportunities and partnerships should be maximized with USAID and 
the National Institute of Allergy and Infectious Diseases.  Most notably, the USAID 
Congressional appropriation of $120 million for product development likely will include 
research components. 
• DTBE’s high-priority research projects should include analytics and strong support to 
ensure implementation of these initiatives in the field. 
• CDC’s Small Business Innovation Research Program should be reviewed to identify 
opportunities for TB research grants, such as research funding for the AMD Program 
and TB drugs. 
• DTBE maintains external advisory bodies for both TBTC and TBESC, but ACET should 
provide overall guidance on allocating resources, establishing priorities and identifying 
future directions for all of its research initiatives. 
• Efforts should be made to complete previous TB research projects that were not fully 
analyzed, evaluated and published (e.g., a TBESC genotyping study) before DTBE 
initiates new research projects. 
• Consideration should be given to conducting TB research in the following areas: 
o The feasibility of forming TB teams in primary care settings in order to improve TB 
treatment completion rates. 
o The viability of developing a TB vaccine for prevention. 
o The role of social determinants of health in targeting populations at risk for TB. 
o A meta-analysis of ongoing studies that are comparing various LTBI screening tests. 
o Host factors that drive the progression from LTBI to active TB disease. 
o Translation of TB research into meaningful TB control practice in the field (e.g., use 
of 3HP, gene expression and other technical advances). 
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o Rigorous cost-effectiveness studies and economic evaluations of TB prevention and 
elimination. 
Ms. Cole returned the discussion to the USPSTF draft research plan for LTBI screening and 
entertained a motion for ACET to submit its formal response by the July 2, 2014 deadline.  
Based on its previous discussion, ACET’s formal response would address four major gaps. 
1. Patients with HIV and diabetes as well as those taking TNF blockers are excluded from 
LTBI screening due to the “inaccurate” assumption that LTBI screening and treatment 
are part of a standard disease management protocol for these patient populations in 
primary care settings. 
2. Persons in correctional settings are excluded from LTBI screening. 
3. The role of public health clinics in LTBI screening is not mentioned. 
4. Data from TB contact investigations will not be considered in the USPSTF systematic 
review. 
Chair’s call for a vote Motion properly made by Dr. Ana Alvarez for ACET to submit its 
formal response to the USPSTF draft research plan for LTBI 
screening 
Motion seconded by Dr. Gail Cassell 
Outcome of vote Motion and second withdrawn 
Next steps A small writing group will present a draft of ACET’s formal response 
for the membership to discuss, revise and vote on during the 
Business Session. 
 
Dr. Dean noted that several members expressed an interest in submitting comments on the 
USPSTF draft research plan outside of ACET.  As a result, she clarified the difference between 
an “individual comment” and a “formal ACET response.”  Individual ACET members are free to 
comment on any document as private citizens or members of other institutions or organizations, 
but cannot submit comments on behalf of ACET.  A formal ACET response to any document 
must be presented, discussed and voted on by the entire membership during a public in-person, 
webinar or teleconference meeting. 
Update by the ACET Essential Components Workgroup 
 
Eric Brenner, MD 
Adjunct Associate Professor, Department of Epidemiology and Biostatistics 
University of South Carolina 
ACET Member & Essential Components Workgroup Chair 
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Dr. Brenner covered the following topics in his update to ACET on the workgroup’s recent 
activities.  The workgroup’s initial effort to address its charge was to review CDC’s September 8, 
1995 MMWR publication, Essential Components of a Tuberculosis Prevention and Control 
Program.  The workgroup’s review emphasized the need to update and replace CDC’s 1995 
document with more recent guidance on TB essential components for 2015 and in the 
foreseeable future. 
The workgroup drafted its report, Essential Components of a Tuberculosis Prevention and 
Control Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis, 
and planned to present the document during the current meeting.  However, the revision 
process is still underway.  Dr. Brenner announced that the workgroup’s draft report would be 
presented during the next meeting for ACET’s consideration, deliberation and formal vote.  In 
the interim, he highlighted the key points of the draft report. 
• The Summary/Introduction section describes the purpose and context of the report by 
providing a comprehensive background on the essential components of TB prevention 
and control programs. 
o The marked decline in TB rates in the United States over the past 60 years. 
o The need to continue to implement well-established strategies to make further 
progress on TB control in the United States. 
o The responsibility of state/local health departments in TB prevention and control. 
o Other important activities for TB control beyond the essential elements:  data-driven 
analyses to prioritize TB control efforts; coordination of patient care and other TB 
control activities through collaborative networks with partners; and incorporation of 
the most current TB diagnosis, treatment and control strategies into routine program 
activities. 
• Essential training and education components are recommended in various formats for 
TB staff at multiple levels, healthcare providers and community members. 
o A “TB Control 101” course with an orientation and training session should be 
targeted to all TB control staff, including newly-hired TB controllers and more 
experienced TB controllers who could benefit from a refresher course on the 
essential components. 
o A condensed technical summary should be targeted to non-TB public health staff 
that needs education on TB control.  Bureau chiefs with responsibility for multiple 
disease control programs should have knowledge of basic TB control elements.  
Directors of other disease control programs, particularly those in low-incidence 
areas, should be knowledgeable in this area to effectively collaborate with TB staff in 
complex outbreak investigations. 
o National standards for essential components should be targeted to TB control 
programs.  These standards would be useful for internal and external reviewers 
during evaluations of TB programs and also for health departments, legislators and 
other funding entities for advocacy efforts. 
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• The data sections are being reviewed to determine whether updates are needed in 
specific areas. 
o Case reporting, including data collection, analysis and program evaluation 
o TB registry data 
o Protection of patient confidentiality 
o Drug resistance surveillance 
• Global revisions are being made to the terminology as appropriate:  replace “tuberculin 
skin testing” with “testing for TB infection” and replace “screening” with “targeted testing.” 
• A new process is being recommended that will allow TB controllers to access documents 
related to the essential components of TB prevention and control in a more efficient and 
rapid manner.  Instead of separately accessing each CDC statement through the 
CDC.gov website, for example, a succinct and up-to-date PDF file would include links 
and references to all documents that have been published over time. 
• Additional guidance will be included based on the overview of CDC’s new AMD Program 
that was presented during the current meeting. 
o Each TB program needs to maintain capacity for traditional laboratory methods in 
addition to developing skill sets related to AMD.  The results of AMD methods (e.g., 
WGS and analyses requiring advanced bioinformatics techniques) increasingly will 
need to be available to all programs as more progress is made toward TB 
elimination the United States. 
o Depending on the burden of TB and public health laboratory capacity, jurisdictions 
may take different approaches to incorporating AMD capacity into their programs.  
These strategies include developing in-house capabilities, forming regional 
collaboration with neighboring states, and creating protocols for collaboration with 
AMD capabilities that are emerging at CDC. 
• Decisions will be made on whether language in the 1995 CDC document regarding 
community coalitions is still needed. 
Update by the ACET Corrections Workgroup 
 
Jane Carter, MD, ACET Member 
Associate Professor, Alpert School of Medicine at Brown University 
The Miriam Hospital 
Dr. Carter reported that the workgroup has been dormant.  In 2012, ACET formally approved 
the workgroup’s draft recommendations and DTBE took subsequent actions on many of these 
items.  In 2013, ACET formally approved the reestablishment of the workgroup due to the need 
for an ongoing focus on TB in correctional settings.  However, the workgroup has not conducted 
any activities since that time.  Dr. Carter and Ms Sarah Bur, the ex-officio member for the 
Federal Bureau of Prisons, are the only two remaining members on the workgroup. 
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Dr. Carter proposed the reestablishment of the workgroup with volunteers from the current 
membership.  The workgroup’s initial charge would be three-fold:  (1) evaluate activities DTBE 
has conducted to address ACET’s previous recommendations on TB in correctional settings; (2) 
review recent publications on the dramatic contribution of correctional settings to TB cases; and 
(3) serve as a liaison between ACET and the DTBE Corrections Workgroup. 
ACET agreed by consensus to reestablish the Corrections Workgroup with the following 
members. 
• Dr. Jane Carter, Chair (ACET member) 
• Ms. Sarah Bur (ex-officio member, Federal Bureau of Prisons) 
• Dr. Diana Elson or Ms. Tiffany Moore (ex-officio member, U.S. Immigration and Customs 
Enforcement) 
• DTBE staff (to be named) for technical support and expertise 




Associate Director for Policy and Issues Management, DTBE 
Centers for Disease Control and Prevention 
Ms. Cronin covered the following topics in her update to ACET on the workgroup’s recent 
activities.  Data show that problems related to SLD shortages have been ongoing for more than 
10 years.  Reports submitted to CDC from the field also identified shortages in two critical first-
line drugs:  INH and Tubersol that eventually affected the supply of Aplisol.  The limited number 
of manufacturers also plays a significant role in TB drug shortages. 
CDC released seven papers to widely publicize the TB drug shortage problem, but no long-term 
solutions have been proposed to date.  Most notably, the federal government cannot require 
industry to manufacture drugs or target the distribution of drugs to at-risk populations.  Private 
companies are free to discontinue the manufacture of any product at any time.  CDC is 
exploring potential options to overcome barriers to the TB drug shortage problem. 
• The federal government has been successful in improving communications regarding 
impending drug shortages and locations to access products during shortages.  Drug 
companies, particularly those that manufacture products for communicable diseases and 
serious or life-threatening illnesses, are required to notify FDA of anticipated shortages 
or their plans to discontinue the production of drugs. 
• FDA has discussed the possibility of offering incentives to U.S. manufacturers to remain 
in the market, granting approval to overseas companies to sell their products in the 
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United States through the TB Global Drug Facility (GDF), and mitigating the $500,000 
application fee for FDA approval. 
• An early warning system has been established in which TB controllers in the field notify 
CDC of drug shortages.  CDC then conveys the information to FDA. 
• CDC developed a system to rapidly track existing inventories of influenza vaccine and 
widely publicize the availability of these products.  CDC is discussing the possibility of 
creating a similar system for TB drugs. 
• CDC has engaged its partners in discussions to determine the feasibility of establishing 
a National TB Pharmaceutical Repository. 
• The option of a “temporary buffer” is being explored in which a certain amount of drugs 
would be retained and circulated to TB controllers prior to their expiration date.  
However, CDC’s assessment showed that $21 million would be needed to retain a six-
month supply. 
• Pooled purchasing was not found to be a viable option because the market for TB drugs 
would need to be expanded with more patients.  Drug sharing also would not be feasible 
because inflexible funding streams would not allow a state health department to share its 
drugs with another state.  However, this barrier potentially could be resolved through 
memoranda of understanding in which states would share resources in a public health 
event. 
• The purchase of TB drugs through the GDF was not found to be an effective solution to 
address the drug shortage problem.  The drugs must be purchased through the GDF 
stockpile, but none of these drugs are FDA approved as required.  Moreover, only three 
SLDs are available in the GDF and must be purchased in bulk. 
ACET agreed that the TB drug shortage problem should be one of the high-priority, broad 
themes in its new strategic process for resolutions/recommendations.  Several members noted 
that ACET’s long-term focus and ongoing persistence would be needed to make progress on 
this important topic.  The members described a number of issues that should be considered in 
ACET’s future guidance on TB drug shortages. 
• Reframe TB drug shortages as a “public health emergency” in all future guidance. 
• Provide guidance that includes clearly defined strategies to assist FDA in resolving 
Congressional or legislative barriers to TB drug shortages. 
• Elevate the discussion on TB drug shortages to a much higher level by directing 
guidance to the HHS Secretary and Dr. Margaret Hamburg, Commissioner of FDA. 
• Link guidance on the TB drug shortage problem to broader antimicrobial resistance 
efforts in the United States.  Most notably, Congress has acknowledged antimicrobial 
resistance as a national health threat.  A new high-level federal committee has been 
formed to address antimicrobial resistance long-term. 
With no further discussion or business brought before ACET, Ms. Cole recessed the meeting at 
4:46 p.m. on June 9, 2014. 
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Opening Session: June 10, 2014 
Hazel Dean, ScD, MPH 
Deputy Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
ACET Designated Federal Officer 
Dr. Dean conducted a roll call to determine the ACET voting members, ex-officio members and 
liaison representatives who were attending the meeting either in person or remotely.  She 
announced that ACET meetings are open to the public and all comments made during the 
proceedings are a matter of public record. 
Dr. Dean reminded the ACET voting members of their responsibility to disclose any potential 
individual and/or institutional conflicts of interest for the public record and recuse themselves 
from voting or participating in these matters.  None of the voting members publicly disclosed any 
individual or institutional conflicts of interest for the record that were new or different than those 
declared on day 1 of the meeting. 
Dr. Dean announced that the voting members and ex-officio members in attendance constituted 
a quorum for ACET to conduct its business on June 10, 2014.  She called the proceedings to 
order at 8:32 a.m. and welcomed the participants to day 2 of the ACET meeting. 
Asian Health Services Perspective: Community Partners in the Management of TB 
Susan Huang, MD 
Chief Medical Officer 
Asian Health Services 
Dr. Huang described the perspective of Asian Health Services (AHS) on the role of community 
partners in the management of TB.  She explained that the purpose of her presentation would 
be three-fold:  (1) improve TB control and elimination among Asian American/Pacific Islanders 
(AAPIs); (2) better understand the role and value of Federally Qualified Health Centers (FQHCs) 
as community partners in this effort; and (3) inform next steps for TBESC to plan for community 
partnerships. 
The Community Health Center (CHC) movement is based on the early principles of community-
based primary care and social medicine that were initiated in the 1800s in South Africa.  As a 
result of the War on Poverty and the Civil Rights Movement in the 1960s, these principles were 
introduced in the United States with a focus on epidemiology, population statistics, and 
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community organization and outreach.  A $1.2 million grant was awarded to two physicians in 
1965 to pilot two CHC sites in Boston and Mississippi. 
CHCs are unique due to three major factors.  First, CHCs are community-responsive and must 
be located in federally-designated medically underserved areas or target services to 
underserved populations (e.g., racial/ethnic minorities, persons with low English proficiency 
(LEP), persons with low incomes, under-insured and uninsured persons and homeless 
persons).  The 1,300 CHCs cover >9,000 locations in the United States and serve >22 million 
patients. 
Second, CHCs are heavily regulated.  Legislation requires CHCs to be nonprofit organizations; 
adhere to the “51% rule” in which the majority of its board members must be CHC users or 
community consumers; and submit annual reports to HRSA on patient demographics, staffing, 
clinical quality and costs.  Third, CHCs are patient-centered and are the only part of the 
American healthcare system that allows patients and the community to guide their individual 
primary care providers, policies and programs. 
The East Bay Asians for Community Action conducted a needs assessment in the early 1970s 
that showed the majority of Asian residents lacked health care due to poverty and/or language 
barriers.  These early efforts led to the establishment of AHS in Oakland, California in 1974 with 
a foundation based on civil rights, immigration status and community organization. 
AHS is an FQHC with a mission to serve and advocate for the Asian community regarding its 
health rights and also to assure access to healthcare services regardless of income, insurance 
status, language or culture.  AHS’s 38 FTEs of licensed medical, dental and behavioral health 
professionals serve 24,000 patients with >110,000 visits annually.  AHS’s target populations 
include AAPIs and LEP groups.  
In terms of demographics, 54% of AHS patients are below the Federal Poverty Level (FPL) and 
43% are at 100%-200% of the FPL.  Compared to the poverty level of AAPI populations in 
Oakland (22%), Alameda County (11%) and the total county (10%), AHS patients are poorer. 
ACA has been successful in reducing the uninsured status of AHS patients from 45% to 10%. 
AHS patients are defined by federal guidelines as an LEP group and face linguistic isolation at a 
much higher rate (90%) compared to AAPI populations in Oakland (48%), Alameda County 
(31%) and the total county (9%).  AHS provides its patients with onsite interpretation for 12 
different Asian languages.  Unlike other FQHCs, AHS has a much larger patient population of 
seniors (>20%). 
The AHS infrastructure includes three primary care medical homes that provide a full spectrum 
of services across the life cycle, two school-based clinics, one integrated specialty mental 
health/primary care site, two primary oral health clinics, and a rotating school-based dental 
services team.  Other parts of AHS’s infrastructure include pediatric, teen and geriatric clinics, 
 
DRAFT Minutes of the Meeting 
Advisory Council for the Elimination of Tuberculosis 
June 9-10, 2014  ♦  Page 35 
 
acupuncture and manual medicine, group visits, specialty care, and advanced specialties in 
dental care.  AHS recently made a full transition to electronic health records (EHRs) for both its 
primary care medical homes and dental services sites. 
AHS offers several programs and services that are unique to its AAPI patient population.  
Patient and family advisory councils and community liaison units were established to engage 
the community in important local issues, such as voter rights, health education and advocacy 
efforts.  A language cooperative was formed to provide oral and written translation services to 
patients and other community providers and also to offer certified training to interpreters.  A 
clinical research department was developed to conduct community-based participatory research 
on engaging difficult-to-reach AAPI populations.  A dental residency program was created. 
AHS has included universal TB testing in its screening and disease management protocols for 
patients due to the high incidence of active TB and LTBI in AAPI populations.  The EHR 
includes an electronic reminder for providers to perform TB screening.  The status of the TB test 
must be documented for each patient.  AHS also uses electronic practice management records 
to collect patient demographics data (e.g., primary language, insurance status, country of origin 
and immigration status).  AHS’s position is that more consistent and frequent use of these data 
over time will play an important role in mapping the epidemiology of TB cases in AAPI 
populations prior to U.S. entry. 
AHS maintains a number of essential partnerships to conduct its activities.  The Alameda 
County Public Health Department reports, tests and tracks active TB cases; regularly conducts 
grand rounds and in-services at AHS’s facilities; and provides direct, point-of-care medical 
consultation and case management.  The Community Health Center Network was formed in 
1996 and includes eight CHCs that deliver services to their specific target populations in 
Alameda County, California:  AAPIs, African Americans, Hispanics and Native Americans. 
The Association of Asian Pacific Community Health Organizations (AAPCHO) was established 
in 1987 and now has a membership of >34 FQHCs and other community health organizations.  
AAPCHO is dedicated to advocacy and collaboration for the improvement of health and health 
access for Asian American, Native Hawaiian and Other Pacific Islanders (AA/NHOPIs) 
nationwide.  AAPCHO members collectively serve >500,000 AAPIs across the country. 
The Community Health Applied Research Network (CHARN) was established in 2010 by HRSA 
to build research capacity and serve as a data warehouse for safety net CHCs.  CHARN 
includes 18 CHCs in nine states and targets research to the health and healthcare of 
underserved populations.  The four CHARN nodes collaborate with their individual academic 
partners and submit data with a standardized dataset. 
The AAPCHO research node includes four CHCs that primarily serve AA/NHOPIs and account 
for 80% of CHARN data on these populations.  The four CHCs have unique cultural and 
linguistic expertise and effective engagement with its highly diverse target populations.  To date, 
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2006-2012 data have been collected on >850,000 AA/NHOPI patients for the CHARN dataset:  
patient demographics (e.g., language and insurance status), provider encounters, diagnoses 
(e.g., HIV, TB, hepatitis and chronic diseases), and laboratory and medication data.  The 
CHARN data will be essential in identifying significant health disparities in AA/NHOPI patients. 
The next steps in these efforts will focus on three major activities.  First, data will be refined.  
CHARN will integrate new data on enabling services and utilization (e.g., interpretation services, 
community resource linkages, eligibility processing, and utilization of emergency departments/ 
hospitals).  AAPCHO will expand its network data with the addition of new data on enabling 
services and data from other CHCs that serve AA/NHOPIs.  AHS will expand the use of EHR 
technology to focus on population-based health management, conduct panel management on a 
much broader level, and assure patient-level linkage to care from diagnosis to management and 
risk reduction of various illnesses and diseases. 
Second, efforts will be targeted to identifying and leveraging long-term funding streams to 
ensure AHS’s services to patients are sustained over time.  Most notably, <1% of federal 
healthcare-related grant funding was targeted to CHC-type populations in 1986-2000, but AA/ 
NHOPIs account for >6% of the U.S. population.  Third, AHS will collaborate with TBESC to 
strengthen relationships between FQHCs and public health and promote the translation of 
community-based research or data into best practices nationwide. 
ACET discussed the following topics with Dr. Huang on AHS’s management of TB in the AAPI 
community. 
• The critical need to tailor the AHS model for other populations with high rates of active 
TB disease and LTBI to achieve the national TB elimination goal. 
• The importance of replicating AHS’s research component in other CHCs. 
• Strategies AHS implemented to enroll and retain patients in ACA. 
• The need for CHCs to improve LTBI reporting to public health departments. 
ACET applauded Dr. Huang for her compelling and eloquent presentation.  Several members 
commended AHS on its outstanding accomplishments, particularly its leadership in engaging 
difficult-to-reach AAPI populations in the healthcare system.  ACET found AHS to be a model 
for other CHCs in the nation to deliver services to their target populations.  The members 
proposed three areas that should be considered in providing guidance on the role of CHCs in 
TB. 
• The 2005 American Thoracic Society/CDC/Infectious Diseases Society of America 
guidelines recommended four priority strategies for TB control in the United States.  
However, ACET should craft language to recommend public health/CHC collaborations 
as an additional priority strategy when the guidelines are updated. 
• DTBE should collect and analyze TB data from CHCs, such as the number of TB 
patients served, prevalence of LTBI, and rates of TB treatment initiation and completion.  
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These data could be used to determine the impact of TB in CHC populations on broader 
TB control efforts in the United States.  DTBE should explore whether TBESC could use 
CHARN as a research mechanism in this effort. 
• ACET should formulate guidance to recommend making TB infection a nationally 
reportable disease.  Surveillance data need to be presented to Congress to demonstrate 




Ms. Cole opened the business session and called for ACET’s review, discussion and/or formal 
action on the following topics. 
Topic 1: Draft ACET Meeting Minutes 
Ms. Cole entertained a motion for ACET to approve the previous meeting minutes.  A motion 
was properly placed on the floor by Dr. Jane Carter and seconded by Dr. Gail Cassell for ACET 
to approve the previous meeting minutes. 
ACET unanimously adopted the Draft March 4, 2014 Meeting Minutes with no changes or 
further discussion. 
Topic 2: Status Report on the March 2014 Action Items 
Ms. Cole moderated ACET’s discussion on the status of the action items that were raised during 






1. CDC to provide clarification on specific 
criteria that were used to categorize and 
define “antibiotic-resistant infections.” 
Completed; Dr. Philip LoBue circulated an e-mail 
message to ACET on March 5, 2014 with 
definitions for each type of threat and CDC’s 
criteria to rank antibiotic-resistant infections into 
specific threat categories. 
2. ACET to routinely revisit and monitor the 
impact of DTBE’s strategic priorities and 
proposed budget scenarios. 
Ongoing; ACET will develop a more effective 
and responsive approach to DTBE’s request for 
guidance.  For example, ACET does not 
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routinely provide DTBE with direct responses to 
“advice requested from ACET” described on 
presenters’ summary sheets. 
3. ACET to develop formal guidance to assist 
CDC in obtaining a USPSTF grade for TB 
preventive care and Medicaid coverage of 
this service. 
Completion pending; ACET will discuss, revise 
and vote on its formal response to the USPSTF 
draft research plan for LTBI screening during the 
Business Session. 
Ongoing; ACET will routinely revisit and monitor 
the status of the USPSTF systematic review 
process for LTBI screening in order to provide 
input as needed. 
• If LTBI screening is approved, ACET will 
provide guidance to assure that Medicaid 
coverage is a national rather than a state-
specific standard. 
• If LTBI screening is not approved, ACET will 
provide guidance to the Community Preventive 
Services Task Force.   
4. ACET to provide the Essential Components 
Workgroup with more specific guidance on its 
proposed framework. 
Completion pending; ACET will discuss and 
propose revisions to the workgroup’s draft report 
that will be presented for a formal vote during the 
next meeting. 
5. ACET to propose strategies to widely 
publicize the availability of TB prevention and 
control guidelines for incarcerated 
populations. 
Completion pending; The ACET Corrections 
Workgroup will present the proposed strategies 
for ACET’s consideration and discussion during 
the next meeting. 
6. ACET to continue to provide CDC and its 
partners with concrete advice to address TB 
drug/biologic shortages in the United States. 
Ongoing; ACET will take several actions to 
maintain the TB drug shortage problem as a 
high-priority issue requiring a persistent, long-
term focus. 
• ACET will consider the update by the DTBE 
Drug Shortages Workgroup on the previous 
day and follow-up suggestions proposed by 
the members in formulating future guidance. 
• ACET will directly request or ask Dr. Frieden 
to invite a high-level FDA official to attend the 
next in-person meeting:  Dr. Margaret 
Hamburg (Commissioner of FDA) or Dr. 
Edward Cox (Director, FDA Office of 
Antimicrobial Products).  Based on the 
appropriate chain of command, Dr. Gail 
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Cassell (ACET member) will follow-up on 
ACET’s request by directly communicating 
with Dr. Hamburg.  ACET will clearly define 
objectives for FDA to address during the 
meeting, such as limitations on the importation 
of TB drugs/biologics into the United States 
from GDF and FDA’s perspective on potential 
strategies to resolve these barriers. 
• ACET will communicate with Dr. Sheldon 
Morris, the ex-officio member for FDA, to 
determine reasons for his persistent absence 
from ACET meetings.  ACET will emphasize 
the critical need for Dr. Morris to attend 
meetings to provide FDA’s perspective on the 
important issue of TB drug shortages in the 
United States. 
7. ACET to identify opportunities for CDC to 
apply global experiences, lessons learned 
and research from TB BASICS to TB control 
at national, state and local levels in the 
United States. 
Ongoing; ACET will continue to address this 
issue.  In the interim, ACET provided CDC with 
feedback on its new strategic approach to 
reduce TB among foreign-born populations in the 
United States through global TB activities. 
8. CDC to report the status of ACET’s 
outstanding resolutions. 
Completed; DTBE prepared and distributed three 
spreadsheets with all of the items that were 
placed for a formal ACET vote in 2011, 2012 and 
2013.  ACET engaged in an extensive 
discussion on the status of these items. 
9. ACET to maintain a small standing workgroup 
to plan and draft future agendas in 
collaboration with CDC staff. 




Topic 3: USPSTF Draft Research Plan on LTBI Screening 
Dr. Susan Dorman, an ACET member, presented a draft of ACET’s formal response to the 
USPSTF draft research plan on LTBI screening.  ACET extensively discussed and suggested 
several changes to the draft response, particularly in the areas of populations, settings and 
study designs that the USPSTF has proposed to be included or excluded from LTBI screening. 
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The revised response was presented for a vote based on the changes ACET proposed during 
the discussion. 
The Advisory Council for the Elimination of Tuberculosis (ACET) provides advice and 
recommendations regarding the elimination of tuberculosis (TB) to the Secretary, 
Department of Health and Human Services; Assistant Secretary for Health; and Director, 
Centers for Disease Control and Prevention (CDC).  ACET affirms the importance of 
answering the Key Questions in a systematic review in order to inform inclusion of 
screening for latent tuberculosis infection (LTBI) in adults in the U.S. Preventive Service 
Task Force recommendations.   
For consideration, ACET has the following comments on the draft Research Plan: 
Section II.  Proposed Key Questions to be Systematically Reviewed 
Question 1.  Four separate outcomes are included in the draft question.  ACET 
recommends that these outcomes be considered separately as separate questions, 
specifically: 
What is the direct evidence that targeted screening for LTBI in asymptomatic adults at 
increased risk for developing active TB (such as persons in populations with a high 
prevalence of active TB or with documented increased risk for progression from LTBI to 
active TB):  
a) Improves quality of life? 
b) Reduces progression to active TB? 
c) Reduces transmission of TB? 
d) Reduces mortality? 
An additional important consideration within Question 1 is whether the Question 1 target 
population (asymptomatic adults at high risk for developing active TB) receives care in 
primary care clinics.  This could be addressed as a Key Question or Contextual Question.  
Question 3.  Four separate outcomes are included in the draft question.  ACET 
recommends that these outcomes be considered separately as separate questions, 
specifically: 
For adults with LTBI, to what extent does treatment using CDC-recommended pharma-
cotherapy regimens: 
a) Improve quality of life? 
b) Reduce progression to active TB? 
c) Reduce transmission of TB? 
d) Reduce mortality? 
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Section IV.  Proposed Research Approach 
Populations:  Studies of close contacts of persons with active TB provide critical 
information that is relevant to all populations at risk for LTBI.  Those studies should not 
be excluded from the Evidence Report. 
Settings:  Correctional facilities are settings in which primary care is provided.  Therefore, 
correctional facilities should not be excluded from the Evidence Report. 
The HIV epidemic has evolved such that HIV clinics are settings in which primary care is 
provided.   Therefore, HIV clinics should not be excluded from the Evidence Report. 
Public health clinics serve as primary care settings and should be considered a potential 
target of this review.  
Chair’s call for a vote Motion properly made by Dr. Robert Horsburgh for ACET to submit 
its revised formal response to the USPSTF draft research plan for 
LTBI screening 
Motion seconded by Dr. Ana Alvarez 
Outcome of vote Motion unanimously passed by 9 ACET voting members 
Next steps Ms. Cole will electronically submit ACET’s formal response to the 
USPSTF draft research plan by the July 2, 2014 deadline.  Ms. Cole 
also will e-mail the response to the entire ACET membership. 
Topic 4: ACET’s Advisory Role in TB Elimination 
Ms. Cole moderated ACET’s discussion on assessing, clarifying and improving its existing 
resolution/recommendation process to have a greater impact on TB elimination.  As a starting 
point in ACET’s future guidance, she reiterated the six recommendations in the 2000 IOM report 
to accelerate progress toward TB elimination. 
1. Maintain control of TB 
2. Accelerate the rate of decline of TB 
3. Develop new tools to diagnose and treat TB 
4. Increase involvement in global TB efforts 
5. Mobilize and sustain public support for TB 
6. Track progress toward TB elimination 
Ms. Cole asked the members to provide feedback on a systematic process or next steps for 
ACET to regularly review progress toward TB elimination and provide effective guidance.  For 
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example, ACET could structure future meetings with updates on activities that have been 
conducted to date to address specific IOM recommendations.  ACET could use the updates as 
the basis to begin formulating guidance on TB elimination. 
• ACET’s next steps to improve its advisory role in TB elimination should be targeted to 
three major areas:  (1) review existing data to identify gaps in implementation of the IOM 
recommendations; (2) propose concrete strategies to fill these gaps and accelerate 
progress; and (3) present the findings to the new DTBE Director to assure alignment 
with DTBE’s strategic plan, vision and future direction for TB elimination. 
• ACET’s ongoing focus on the TB drug shortage problem in the United States should be 
linked to IOM recommendation 1 to maintain control of TB.  ACET’s guidance should 
acknowledge that the private sector will play a much larger role in the procurement and 
availability of drugs for TB treatment in a health reform environment through monitored 
or low-cost drugs. 
• ACET initially should direct its guidance to IOM recommendations 2, 4 and 5 because 
the least amount of progress has been made in these three areas. 
o ACET’s guidance on item 2 should focus on LTBI.  (1) Progress on the completion of 
LTBI treatment should be evaluated because the decline in TB rates cannot be 
accelerated without a significant reduction in the incidence of LTBI.  (2) The critical 
role of CHCs in TB elimination should be emphasized.  ACET’s guidance should 
promote Asian Health Services as a CHC model in detecting LTBI in communities 
and support the replication of this effort in CHCs across the country.  (3) “Completion 
of LTBI treatment” should be included as an endpoint in ACET’s recommendation to 
make LTBI a nationally reportable disease.  The Council of State and Territorial 
Epidemiologists (CSTE) should be invited to a future ACET meeting to present the 
criteria and describe the process to add LTBI as a new nationally notifiable disease.  
Prior to formulating this guidance, however, ACET should review data, experiences 
and lessons learned from California and Massachusetts to carefully weigh the 
benefits and negative implications of national LTBI reporting.  For example, state TB 
programs will have an additional reporting requirement with no new resources and 
LTBI patients will be pressured to undergo treatment.  Representatives from state 
TB programs that would be responsible for national LTBI reporting should be invited 
to a future meeting to provide ACET with insights from the field. 
o ACET’s focus on item 4 would be timely and aligned with CDC’s new strategic 
approach to reduce TB among foreign-born populations in the United States through 
global TB activities. 
o ACET’s expertise and extensive relationships with stakeholder organizations in the 
field would play an important role in item 5 to mobilize and sustain public support for 
TB. 
• ACET should review the Stop TB USA “Call for Action on the Tuberculosis Elimination 
Plan for the United States.”  The report includes a table that illustrates whether progress 
was or was not made in implementing the IOM recommendations as of 2010. 
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• ACET should formulate guidance on the impact of the aging public health workforce in 
hindering TB elimination efforts.  Retirements of TB physicians, nurses and other 
providers as well as the inability to attract new professionals are resulting in the loss of 
TB expertise and knowledge.  ACET’s guidance should emphasize that the national goal 
of TB elimination cannot be achieved without a trained TB workforce in the field.  A TB 
nurse in the field should be invited to a future ACET meeting to educate the new DTBE 
Director on the unique role of this position in TB control compared to other parts of the 
public health workforce. 
• ACET should initiate discussions on innovative strategies for TB elimination (e.g., 
regionalization, global rather than country-specific management of the TB drug supply, 
and application of the Occupational Safety and Health Administration rule for control of 
infectious diseases). 
• ACET should convey its concerns to the HHS Secretary and CDC Director about the 
potential resurgence in TB due to persistent reductions in federal, state and local TB 
funding.  TB elimination cannot be achieved if this effort is inadequately funded.  ACET 
should gather and provide the HHS Secretary and CDC Director with solid data to 
demonstrate the actual magnitude of the TB burden in the United States.  Congress 
might be less likely to decrease TB funding in the future based on data that show 12 
million Americans are living with TB, while ~1.2 million Americans are living with HIV. 
ACET’s extensive discussion on strategies to improve its advisory role in TB elimination resulted 
in a request for a formal resolution. 
Chair’s call for a vote Motion properly made by Dr. Marcos Burgos for ACET to establish a 
new LTBI Workgroup 
Motion seconded by Dr. Robert Horsburgh 
Outcome of vote Motion unanimously passed by 9 ACET voting members 
Next steps Dr. Horsburgh will chair the new workgroup, poll ACET by e-mail to 
identify additional members, and apply ACET’s suggestions to craft the 
charge of the new workgroup. 
• Review existing data to weigh the advantages and disadvantages of 
national LTBI reporting, particularly at state and local levels. 
• Identify barriers to national LTBI reporting and propose strategies to 
overcome these challenges. 
• Explore approaches to redefine or reclassify “latent TB infection” as 
“TB infection” because persons with LTBI are not captured in 
surveillance systems as TB cases. 
• Use the findings to draft and present recommendations for ACET’s 
consideration, deliberation and formal vote. 
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Topic 5: New CDC TB Nurse Consultant 
Dr. Eric Brenner, an ACET member, presented the “New CDC TB Nurse Consultant” resolution 
for ACET’s consideration and discussion. 
Whereas, TB Nurse Case Management (TBNCM) is an effective intervention for use in 
TB control to ensure successful completion of treatment for the TB patient; 
Whereas, the TB Nurse brings a special body of knowledge to case management 
reflected in diplomacy, scientific knowledge, clinical skills, as well as compassion for the 
most fragile members of society; 
Whereas, nurses are the largest single segment of the public health workforce and 
possess core competencies to carry out assessments, policy development, and 
assurance of functions of public health activities; 
Whereas, TBNCM is not only effective but an essential component to the vision of TB 
elimination; 
Whereas, there is an ever increasing shortage of nurses across the country, a National 
TB Nurse Consultant (TBNC) leader is key to promoting, maintaining, and supporting an 
effective public health workforce. 
BE IT RESOLVED, that ACET advises CDC to develop a position for a dedicated TBNC 
to provide national leadership for TB Nurses across the country: 
1. The TBNC will work closely with medical and program consultants to provide 
comprehensive, effective consultative services for public health programs and their 
partners. 
2. The TBNC will advance the body of scientific knowledge and to develop evidenced-
based case management skills as part of the benefits of TBNCM. 
3. The TBNC will collaborate with partners to develop a National TB Nurse Certification 
process to validate the practice of TBNCM. 
4. The TBNC will help promote the national TB Nurse Network Group and be part of 
regular calls with RTMCC nurse consultants. 
5. The TBNC will promote the value of nursing specialty care, especially for the most 
vulnerable populations, in order to improve the public’s health. 
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Ms. Cole explained that only the concept of the TBNC resolution was being presented at this 
time.  ACET would not take formal action until its resolution/recommendation process was 
clarified.  In the interim, she asked for ACET to propose suggestions on the resolution. 
• Obtain feedback from other sources to refine the resolution:  insights from the new 
DTBE Director, expertise from deans of schools of nursing, input from public health 
nurses who are responsible for TB control in the field, and perspectives from the Staffing 
Workgroup for the DTBE strategic planning process. 
• Expand the resolution as a broader TB workforce issue. 
• Determine whether the resolution can be directly linked to ACET’s focus on TB 
elimination.   
Topic 6: IGRA Resolution 
 
Ms. Cole announced that the IGRA resolution is being TABLED to further refine the language 
regarding the TB Technical Instructions.  She noted that ACET also needs to clarify its new 
strategic approach for resolutions/recommendations before taking formal action.  In response to 
Dr. LoBue’s comment, she confirmed that DGMQ staff would be engaged in all of ACET’s future 
communications on the IGRA resolution. 
 
Topic 7: ACET Report to the HHS Secretary (2011-2013) 
 
Ms. Cole announced that Mr. Shannon Jones, former Chair of ACET, submitted the report in 
April 2014 to inform the HHS Secretary of ACET’s priority issues, key areas of focus and major 
recommendations in 2011-2013. 
• TB drug shortages in the United States 
• TB in correctional and detention facilities 
• TB control and continuity of care along the U.S.-Mexico border 
• CDC’s collaborations with federal partners to address problems with the non-travel 
status of infectious TB patients who are scheduled for deportation from the United States  
• TB surveillance 
• Racial/ethnic disparities in TB 
• Decreases in TB funding 
The HHS Secretary sent a letter to CDC acknowledging receipt of the report, but Ms. Cole 
asked ACET to propose next steps in this regard. 
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• Request a meeting with Dr. Frieden, particularly to emphasize decreases in TB funding 
and other important issues outlined in ACET’s report to the HHS Secretary. 
• Thank the Office of the HHS Secretary in writing for responding to ACET’s report and 
use the letter as an opportunity to reinforce two high-priority issues:  (1) the TB drug 
shortage problem in the United States and (2) the need for the new HHS Secretary to 
contact the Mexico MOH to discuss the contribution of Mexico to TB cases in the United 
States. 
Topic 8: ACET Meeting Formats 
Ms. Cole announced that the next three ACET meetings were scheduled for December 2, 2014 
(a webinar), March 3, 2015 (a webinar), and June 2-3, 2015 (an in-person meeting in Atlanta, 
Georgia).  Due to the restoration of a portion of the TB budget, she asked DTBE to respond to 
ACET’s request to convene two in-person meetings and one webinar per year. 
Dr. Dean explained that all agencies across the government are urged to implement cost-cutting 
measures for their Federal Advisory Committees with less expensive platforms than in-person 
meetings.  Due to this directive, ACET’s request for two in-person meetings and one webinar 
per fiscal year likely will not be approved.  As a result, she advised ACET to focus on improving 
the effectiveness of all meetings regardless of the platform.  For example, DTBE significantly 
decreased the number of agenda items to increase the productivity of ACET webinars. 
ACET made several suggestions in follow-up to Dr. Dean’s remarks. 
• Travel expenses for ex-officio members and liaison representatives are not supported by 
their institutions and organizations.  The lack of support would limit their ability to attend 
two in-person meetings per year. 
• Workgroups should be used to identify key strategic issues for each agenda item, 
particularly since Federal Advisory Committee Act rules and regulations do not apply to 
workgroups.  Workgroups could use teleconferences, e-mail communications or other 
platforms to prepare a few agenda items for ACET’s focused discussion and deliberation 
during webinars. 
• CDC should explore the feasibility of requiring a quorum with voting members only.  For 
example, CDC could convene more in-person meetings if travel support was only 
needed for the nine ACET voting members.  The ACET ex-officio members and liaison 
representatives could remotely participate on webinars with no travel costs involved. 
• ACET’s in-person meeting should be the first meeting of the year and structured as a 
strategic working meeting that would be devoted to key agenda items, broad themes and 
formal resolutions. 
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• Efforts should be made for new members to attend their first meeting face-to-face.  New 
members who attend their first two meetings by webinar and have never met their ACET 
colleagues or CDC staff typically feel disconnected and detached from the federal 
advisory process.  CDC also should determine whether ACET’s webinars could be 
replaced with video conferencing technology to ensure that both new and current 
members remain fully engaged. 
Drs. Dean and LoBue responded to two suggestions ACET proposed during the discussion that 
would require major changes to the current meeting format.  First, ACET expressed an interest 
in changing the one-day webinar on December 2, 2014 to a two-day in-person meeting due to 
the appointment of the new DTBE Director and four new ACET members. 
CDC reported that this change would impact the schedule of all future meetings if ACET’s 
request for two in-person meetings per fiscal year (October 1-September 30) is not approved 
and the current meeting format is maintained.  For example, if ACET convenes an in-person 
meeting in December 2014 (i.e., new fiscal year 2015), the next in-person meeting could not be 
held until after October 1, 2015 (i.e., new fiscal year 2016). 
Second, ACET raised the possibility of convening one annual meeting in the Washington, DC 
area to increase participation by the Office of the HHS Secretary and high-level officials in HHS 
agencies.  ACET also emphasized that 13 of its 15 ex-officio members are based in the DC 
metropolitan area. 
CDC reported that a cost analysis was performed to compare support needed for an ACET 
meeting held in Atlanta versus the DC metropolitan area.  Even if an ACET meeting was held on 
the campus of an HHS agency at no cost, the cost analysis showed that a DC meeting still 
would be more expensive than an Atlanta meeting due to the need to support travel for multiple 
CDC staff. 
Despite CDC’s clarifying remarks and ACET’s suggestions to make webinars more effective, 
some members were still concerned about the current meeting format.  The members were in 
favor of formally going on record with a statement that would be conveyed to Dr. Frieden. 
ACET understands that all federal agencies are urged to implement cost-cutting 
measures for their Federal Advisory Committees with less expensive platforms than in-
person meetings.  ACET supports the use of video conferencing technology to hold two 
of its three annual meetings in the future.  At this time, however, ACET is requesting 
CDC support to convene two in-person meetings per fiscal year to address important 
new developments and maintain momentum on critical issues. 
• DTBE will have a new Director for the first time in 20 years.  ACET will miss a 
valuable opportunity to provide guidance to new leadership at the outset while 
DTBE’s priorities and future directions are being established.  With the current 
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meeting format, for example, ACET will not meet the new DTBE Director for nearly 
one year after his/her appointment. 
• TB funding is reduced or remains stable each fiscal year due to the continued decline 
in the number of cases in the United States.  ACET’s guidance at the federal level is 
needed to address threats to TB funding in a consistent and ongoing manner. 
• DTBE continues to solicit and value ACET’s advice on strategies to overcome 
barriers to the TB drug shortage problem in the United States. 
• ACET continues to provide guidance and support to DTBE by raising awareness of 
risks to traditional TB control efforts in the field. 
ACET’s position is that one in-person meeting per year is not an effective, useful or 
helpful approach to provide guidance to CDC.  Webinars do not allow ACET members 
to network, engage in important off-the-record discussions, and make significant 
progress in TB elimination in an ongoing manner.  If CDC truly values ACET’s advice on 
achieving the national TB elimination goal, ACET strongly recommends two in-person 
meetings per year to provide this guidance.   
Topic 9: Outgoing ACET Members 
Dr. Dean presented letters and certificates of appreciation signed by Dr. Thomas Frieden 
(Director of CDC) and Dr. Jonathan Mermin (Director of NCHHSTP) to four ACET members 
whose terms would expire at the end of June 2014:  Drs. Eric Brenner, Marcos Burgos, Jane 
Carter, and Gail Cassell.  The participants joined Dr. Dean in applauding the four outgoing 
members for their valuable service and outstanding contributions to CDC and their excellent 
advisory role as ACET members. 
 
Topic 10: Agenda Items 
Ms. Cole moderated ACET’s discussion, review and summary of new agenda items that were 
raised over the course of the meeting. 
 






DTBE (Dr. Angela Starks) 1. Overview of CDC’s collaborative efforts with the Critical Path 
to TB Drug Regimen, the Diagnostics Workgroup and other 
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partners on developing a new “Global TB Drug Resistance 
Database” 
NCHHSTP (Dr. Wayne Duffus) 2. Update on NCHHSTP’s recent health equity activities  
ACET Membership 
3. Ongoing business items: 
• ACET discussion on its advisory role in TB elimination 
• ACET discussion on its draft resolution for CDC to hire a 
new TB Nurse Consultant, including an overview by a TB 
nurse in the field 
• ACET discussion on strategies to overcome barriers to the 
TB drug shortage problem in the United States 
ACET (Dr. Randall Reves) 
4. Overview of progress made to date in implementing the IOM 
recommendations following the release of Stop TB USA’s 
2010 “Call for Action on the Tuberculosis Elimination Plan 
for the United States” 
HRSA Bureau of Primary Health 
Care (Dr. Theresa Watkins-
Bryant) 
HRSA Office of Quality and Data 
5. Overview of HRSA’s perspective on the ability and feasibility 
of expanding CHCs to focus more on TB elimination efforts 
 
Overview of efforts to include TB in HRSA’s Uniform Data 
System 
 
DTBE 6. Overview of the TB cascade of care that is being targeted to TBESC sites 
Guest Speakers 
7. National LTBI Reporting: 
• Overview by CSTE on the criteria and process to add LTBI 
as a new nationally notifiable disease 
• Overview by state TB programs on the potential impact of 
national LTBI reporting in the field 
Topic 11: Action Items 
Ms. Cole led ACET in a review of the action items that were raised over the course of the 
meeting. 
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Dr. Hazel Dean 1. Provide the ACET Agenda Setting Workgroup with the May 
2014 CHAC agenda as a potential model to develop future 
ACET agendas 
ACET (Dr. Charles Daley) 2. Provide Dr. Ho with data from the six systematic reviews that 
the WHO Task Force commissioned to inform the USPSTF 
systematic review process for LTBI screening 
Dr. Philip LoBue 3. Provide ACET with an inventory of DTBE’s ongoing and 
emerging research projects after the Research Workgroup 
completes this document 
ACET (Ms. Colleen Daniels) 4. Provide Dr. Ades with point-of-contact information for the 
Clinton Health Access Initiative 
ACET (Dr. Gail Cassell) 5. Provide Dr. Huang with point-of-contact information for the 
National Institute of Dental Research and the National 
Institute of Child Health and Human Development 
ACET Membership 6. Follow-up with the new HHS Secretary on the ACET 2011-
2013 report 
ACET Chair and DFO 7. Schedule briefings with Dr. Frieden or his designee after 
each in-person meeting to summarize key outcomes and 
elevate the importance of TB at the level of the CDC Director 
Public Comment Session 
Ms. Cole opened the floor for public comments; no participants responded. 
Closing Session 
Ms. Cole thanked the members for providing excellent and thoughtful input over the course of 
the meeting to improve ACET’s advisory role and also for continuing to contribute their expertise 
to achieve the national goal of TB elimination.  Ms. Cole asked the participants to join her in 
applauding Dr. Dean, Dr. LoBue, Ms. Margie Scott-Cseh, the ACET Committee Management 
Specialist, and other CDC staff for their outstanding support of ACET meetings.  The 
participants commended Ms. Cole for her superb leadership as the ACET Chair. 
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The next three ACET meetings are scheduled for December 2, 2014 (a webinar), March 3, 2015 
(a webinar), and June 2-3, 2015 (an in-person meeting in Atlanta, Georgia), but these dates are 
not confirmed.  In response to ACET’s request, the Agenda Setting Workgroup and DTBE will 
revisit the dates and platforms of these meetings.  ACET asked DTBE to change the one-day 
webinar on December 2, 2014 to a two-day in-person meeting due to the appointment of the 
new DTBE Director and four new ACET members.  ACET’s request for two in-person meetings 
per fiscal year will be conveyed to Dr. Frieden. 
With no further discussion or business brought before ACET, Ms. Cole adjourned the meeting at 
1:56 p.m. on June 10, 2014. 
       I hereby certify that to the best of my 
       knowledge, the foregoing Minutes of the 
       proceedings are accurate and complete. 
___________________    ___________________________________ 
Date       Barbara Cole, RN, MSN, PHN 
       Chair, Advisory Council for the 
       Elimination of Tuberculosis 
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